Protein based chimeric vaccine for dyslipidemia & atherosclerosis
A protein-based chimeric vaccine targeting ApoC-III, PCSK-9, and ANGPTL3 addresses the residual cardiovascular risk in dyslipidemia and atherosclerosis by inducing specific immune responses to manage lipid levels and plaque formation.
Patent Information
- Application Number
- PCT/IB2024/054972
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-25
- Filing Date
- 2024-05-22
- Publication Date
- 2024-11-28
AI Technical Summary
Current treatments for dyslipidemia and atherosclerosis, such as lowering LDL-C levels, do not completely eliminate cardiovascular risk, and there is a need for a more effective therapeutic approach to manage elevated lipid levels and associated cardiovascular diseases.
A protein-based chimeric vaccine comprising novel polypeptides such as ApoC-III, PCSK-9, and ANGPTL3, conjugated with immunogenic carriers and linkers, is developed to induce specific immune responses and treat dyslipidemia and atherosclerosis.
The vaccine effectively induces immunogenic responses, potentially reducing lipid levels and plaque formation, thereby addressing the limitations of existing treatments for dyslipidemia and atherosclerosis.
Smart Images

Figure IMGF000033_0001 
Figure IMGF000034_0001 
Figure 00000054_0000
Abstract
Description
[0001] Protein Based Chimeric Vaccine For Dyslipidemia & Atherosclerosis Field of the Invention The present invention provides vaccine comprising novel protein based chimeric polypeptides of Formula (I). 5 Peptide A---L---Peptide B---L---Peptide C L2L2 Formula (I) Wherein Each of the peptides A or B or C can independently be an Apolipoprotein C-III (ApoC-III) protein or a Proprotein convertase subtilisin / kexin type 9 (PCSK-9) protein or an Angiopoietin- 10 like protein 3 (ANGPTL3) protein, each of which may be optionally mutated with one or more site specific mutations, wherein further each of Peptide A and Peptide C are linked to a suitable immunogenic carrier and wherein further Peptide A, Peptide B and Peptide C does not represent the same peptide ‘L’ at each occurrence may be absent or present and when present, may be same or different and 15 independently represents a linker as defined hereinafter. In another embodiment, vaccine of the present invention could be DNA or mRNA based vaccine, adenoviral or lentivirus based therapeutic or prophylactic vaccine and relates to the field of treatment of diseases and disorders which are associated with elevated levels of lipids and lipoproteins. More specifically, invention is related to the use of Vaccine to treat Dyslipidemia, 20 Diabetes and Atherosclerosis. In one aspect, the present invention also provides immunogenic composition of protein that comprises polypeptides selected from ApoC-III, PCSK-9 and ANGPTL3 or any combination thereof wherein each polypeptide is coupled with immunogenic carrier. Background of the invention 25 Dyslipidaemia is a risk factor for the development of cardiovascular disease, specifically coronary artery disease. Dyslipidaemia encompasses diseases and disorders characterized by or associated with elevated levels of lipids or lipoprotein in blood. Hyperlipidaemia includes hypercholesterolemia, hypertriglyceridemia, combined hyperlipidaemia. A harmful, atherogenic lipid profile includes elevated serum levels of low-density lipoprotein cholesterol (LDL-C), low serum levels of high- density lipoprotein cholesterol (HDL-C), and elevated serum triglycerides (TG). LDL-C tend to promote the formation of fatty plaques in arteries. Their role in the pathophysiology of cardiovascular disease is well understood and LDL-Cs are the therapeutic target of certain drugs, including HMG-CoA reductase inhibitors (statins). Although lowering LDL-C reduces cardiovascular risk, it does not completely eliminate it; up to 19% of those with therapeutically optimized LDL-C levels still go on to have a cardiovascular event. Improving levels of HDL also is a therapeutic goal as these molecules transport LDL from peripheral vessels to the liver and can, at higher levels, reduce LDL-C in the serum. Moreover, high serum triglycerides independently indicate an increased risk of, for example, cardiovascular disease, diabetes, metabolic syndrome, and obesity. Thus, medical management of serum triglycerides decrease the likelihood and / or extent of cardiovascular disease. [1, 2] The present invention relates to protein based novel immunogenic composition, preferably a vaccine composition which may be used as a therapy and / or prophylactic application for dyslipidaemia and atherosclerotic diseases. In a preferred embodiment is provided immunogenic compositions, preferably vaccine compositions comprising three polypeptides i.e. ApoC-III, PCSK-9 and ANGPTL3 conjugated with each other through suitable linkers for the treatment or prevention of dyslipidaemia and plaque formation over prolonged period of time. In one more preferred embodiment, the present invention provides immunogenic composition, preferably vaccine compositions that comprises polypeptide ApoC-III, polypeptide PCSK-9 and polypeptide ANGPTL3. Summary of the invention The present invention provides immunogenic compositions, preferably vaccine composition that induces formation of antibodies directed to apolipoprotein C-III (ApoC-III), Proprotein convertase subtilisin / kexin type 9 (PCSK-9) and angiopoietin-like 3 (ANGPTL3) in-vitro and in- vivo. In one aspect, the present invention provides a novel chimeric protein, which can be used as a vaccine when the chimeric protein is conjugated with or is used in combination with suitable immunogenic carrier(s) and suitable adjuvant(s). In a further aspect, the present invention relates to use of vaccines of the present invention which are able to influence the ApoC-III, PCSK-9 and ANGPTL3 mediated immune responses, thereby being suitable for the treatment of hyperlipidaemia, hypercholesterolemia, or atherosclerosis including the complications related to cardiovascular diseases (CVD), which causes morbidity and mortality. In one aspect, the present invention provides polypeptides comprising the ApoC-III, PCSK9 and ANGPTL3 proteins that are conjugated with suitable immunogenic carriers as provided in Formula (II) Universal T cell epitope---L1---ApoC-III---L2---PCSK-9---L2---ANGPTL3---L2--- PADRE Formula (II) Wherein, ApoC-III represents Apolipoprotein C-III, PCSK-9 represents proprotein convertase subtilisin / kexin type 9, ANGPTL3 represents Angiopoietin-like protein 3, PADRE represents Pan HLA-DR binding epitope (Universal active peptide that activates T cells) L1 represents Linker 1 and L2 represents Linker 2, wherein the linkers L1 & L2 may be same or different and may be positioned interchangeably, as described further hereinafter, Universal T cell epitope at N terminus or C terminus and PADRE at C terminus or localized at N terminus. The present invention also provides immunogenic composition, preferably vaccine that comprises polypeptides selected from ApoC-III or PCSK-9 or ANGPTL3 or any combination thereof with suitable adjuvants wherein each polypeptide is coupled with immunogenic carrier. In one aspect, the present invention provides novel protein compositions comprising the polypeptides of ApoC-III, PCSK9 and ANGPTL3 wherein each polypeptide is coupled with immunogenic carrier. In another aspect, the present invention provides novel protein compositions comprising the polypeptides of ApoC-III and PCSK9 wherein each polypeptide is coupled with immunogenic carrier. In another aspect, the present invention provides novel protein compositions comprising the polypeptides of ApoC-III and ANGPTL3 wherein each polypeptide is coupled with immunogenic carrier. In another aspect, the present invention the polypeptides of PCSK9 and ANGPTL3ogenic carrier. The protein compositions of the adjuvant(s) and other suitable excipients. Theesent invention acts as an immunogen.uction of the said vaccine, compositions and invention also relates to a use of the vaccine orion for the treatment or prevention of diseases / or ANGPTL3. ention can be administered to a subject having,clerosis. The immunogenic compositions of the s a prophylactic or therapeutic agent or co-ent for therapeutic usage in dyslipidemia or 30a (+) substance III vaccine (Drug product) with marker (M)ce with human chimeric dyslipidaemia vaccine ith His tag chimeric human protein). nicity study of chimeric subunit protein (With cific human ApoC-III protein antigen (With His Figure 8: Immunogenic response in mice with specific human PCSK-9 protein antigen (With His tag). Figure 9: Immunogenic response in mice with specific human ANGPTL-3 protein antigen (With His tag). Figure 10: Immunogenic response in BALB / c mice with human chimeric dyslipidaemia vaccine by Vaccination at Day 0, Day 28, and Day 84 (Without His tag chimeric human protein) Figure 11: Graphical representation of immunogenicity study of chimeric human protein (Without His tag) using ELISA method. Figure 12: Immunogenic response in mice with specific human ApoC-III protein antigen (Without His tag). Figure 13: Immunogenic response in mice with specific human PCSK-9 protein antigen (Without His tag). Figure 14: Immunogenic response in mice with specific human ANGPTL-3 protein antigen (Without His tag). Figure 15: Dose dependent In-vivo immunogenicity study of chimeric human vaccine in mice- in BALB / c mice. Figure 16: Dose dependent In-vivo immunogenicity study of specific antigen (human PCSK-9, Human ApoC-III and ANGPTL-3) at day 28 in BALB / c mice. Figure17: Immunogenicity study of chimeric human protein with alum and oil in water (Alum+o / w) (50 and 100 μg) combination adjuvant in BALB / c mice. Figure18 A: Immunogenicity study of chimeric vaccine ApoC-III with dual adjuvant system in BALB / c mice. Figure18 B: Immunogenicity study of chimeric vaccine PCSK-9 with dual adjuvant system in BALB / c mice. Figure18 C: Immunogenicity study of chimeric vaccine ANGPTL3 with dual adjuvant system in BALB / c mice. Figure19A: Immunogenicity study of chimeric vaccine ApoC-III with oil in water (o / w) adjuvant in Zucker fa / fa rat study using ELISA method. Figure19B: Immunogenicity study of chimeric vaccine PCSK-9 with oil in water (o / w) adjuvant in Zucker fa / fa rat study using ELISA method. Figure19C: Immunogenicity study of chimeric vaccine ANGPTL-3 with oil in water (o / w) adjuvant in Zucker fa / fa rat study using ELISA method. Figure 20: Functional assay demonstrating rat sera binding with PCSK9 protein by Surface Plasmon resonance. Figure 21: Dose ranging immunogenicity study data of PCSK9 vaccine formulations in vivo in high fat diet fed C57BL / 6 mice model. Brief description of sequences of the present invention: SEQ ID No: 1 depicts amino acid sequence of human apolipoprotein C-III (ApoC-III). SEQ ID No: 2 depicts amino acid sequence of human proprotein convertase subtilisin / kexin type 9 (PCSK-9). SEQ ID No: 3 depicts amino acid sequence of human angiopoietin-related protein 3 preproprotein (ANGPTL3). SEQ ID No: 4 depicts amino acid sequence of universal T cell epitope. SEQ ID No: 5 depicts amino acid sequence of human ApoC-III fragment. SEQ ID No: 6 depicts amino acid sequence of human PCSK9 fragment. SEQ ID No: 7 depicts amino acid sequence of human ANGPTL3 fragment. SEQ ID No: 8 depicts amino acid sequence of pan HLA-DR binding epitope (PADRE) SEQ ID No: 9 depicts amino acid sequence of one of the chimeric protein of the present invention that comprises ApoC-III, PCSK9 and ANGPTL3. Embodiments of the invention In one embodiment, the present invention provides a chimeric protein wherein the chimeric protein comprising polypeptides ApoC-III, PCSK-9 and ANGPTL3, wherein the ApoC-III, PCSK-9 and ANGPTL3 are coupled with each other via one or more suitable linker(s) as per Formula (I): Peptide A---L---Peptide B---L---Peptide C Formula (I) Wherein Each of the peptides A or B or C can independently be an Apolipoprotein C-III (ApoC-III) protein or a Proprotein convertase subtilisin / kexin type 9 (PCSK-9) protein or an Angiopoietin- like protein 3 (ANGPTL3) protein, each of which may be optionally mutated with one or more site specific mutations, wherein further each of Peptide A and Peptide C are linked to a suitable immunogenic carrier and wherein further Peptide A, Peptide B and Peptide C does not represent the same peptide ‘L’ at each occurrence may be absent or present and when present, may be same or different and independently represents a linker as defined hereinafter. In another embodiment, the present invention provides the protein wherein the protein is a combination of atleast two polypeptides selected from ApoC-III and / or PCSK-9 and / or ANGPTL3 wherein each polypeptide is coupled with immunogenic carrier. In another embodiment, the present invention provides the protein wherein the protein is a polypeptide selected from ApoC-III or PCSK-9 or ANGPTL3 wherein each polypeptide is coupled with immunogenic carrier. In one embodiment, the present invention provides the chimeric protein or protein wherein the ApoC-III comprises atleast 2 amino acids, atleast 4 amino acids, atleast 6 amino acids, atleast 8 amino acids, atleast 10 amino acids, atleast 12 amino acids, atleast 14 amino acids, atleast 15 amino acids atleast 19 amino acids, atleast 21 amino acids, atleast 23 amino acids, atleast 26 amino acids, atleast 27 amino acids, atleast 29 amino acids, atleast 32 amino acids, atleast 34 amino acids, atleast 36 amino acids, atleast 39 amino acids, atleast 40 amino acids, atleast 42 amino acids, atleast 44 amino acids, atleast 47 amino acids, atleast 48 amino acids, atleast 52 amino acids, atleast 55 amino acids, atleast 67 amino acids, atleast 77 amino acids, atleast 79 amino acids, atleast 84 amino acids, atleast 95 amino acids or atleast 97 amino acids of the naturally occurring ApoC-III protein. Naturally occurring ApoC-III protein according to the present invention includes, but not limited to, human ApoC-III protein. In one embodiment, the present invention provides the chimeric protein or protein, wherein the PCSK-9 comprises atleast 2 amino acids, atleast 5 amino acids, atleast 7 amino acids, atleast 8 amino acids, atleast 10 amino acids, atleast 13 amino acids, atleast 14 amino acids, atleast 17 amino acids, atleast 18 amino acids, atleast 21 amino acids, atleast 22 amino acids, atleast 24 amino acids, atleast 27 amino acids, atleast 28 amino acids, atleast 30 amino acids, atleast 31 amino acids, atleast 35 amino acids, atleast 37 amino acids, atleast 38 amino acids, atleast 40 amino acids, atleast 42 amino acids, atleast 45 amino acids, atleast 46 amino acids, atleast 48 amino acids, atleast 49 amino acids, atleast 55 amino acids, atleast 60 amino acids, atleast 70 amino acids, atleast 80 amino acids, atleast 85 amino acids, atleast 95 amino acids, atleast 96 amino acids, atleast 100 amino acids, atleast 115 amino acids, atleast 129 amino acids, atleast 157 amino acids, atleast 175 amino acids, atleast 195 amino acids, atleast 220 amino acids, atleast 245 amino acids, atleast 277 amino acids, atleast 310 amino acids, atleast 345 amino acids, atleast 380 amino acids, atleast 390 amino acids, atleast 400 amino acids, atleast 435 amino acids, atleast 455 amino acids, atleast 485 amino acids, atleast 513 amino acids, atleast 537 amino acids, atleast 560 amino acids, atleast 592 amino acids, atleast 617 amino acids, atleast 634 amino acids, atleast 650 amino acids, atleast 670 amino acids, atleast 685 amino acids or atleast 690 amino acids of the naturally occurring PCSK-9 protein. Naturally occurring PCSK- 9 protein according to the present invention includes, but not limited to, human PCSK-9 protein. In one embodiment, the present invention provides the chimeric protein or protein wherein the ANGPTL3 comprises atleast 2 amino acids, atleast 5 amino acids, atleast 6 amino acids, atleast 8 amino acids, atleast 10 amino acids, atleast 11 amino acids, atleast 17 amino acids, atleast 18 amino acids, atleast 19 amino acids, atleast 20 amino acids, atleast 22 amino acids, atleast 25 amino acids, atleast 26 amino acids, atleast 28 amino acids, atleast 31 amino acids, atleast 32 amino acids, atleast 34 amino acids, atleast 36 amino acids, atleast 39 amino acids, atleast 40 amino acids, atleast 42 amino acids, atleast 45 amino acids, atleast 46 amino acids, atleast 49 amino acids, atleast 50 amino acids, atleast 55 amino acids, atleast 60 amino acids, atleast 70 amino acids, atleast 80 amino acids, atleast 85 amino acids, atleast 95 amino acids, atleast 100 amino acids, atleast 107 amino acids, atleast 115 amino acids, atleast 127 amino acids, atleast 145 amino acids, atleast 153 amino acids, atleast 154 amino acids, atleast 155 amino acids, atleast 179 amino acids atleast 187 amino acids, atleast 207 amino acids, atleast 227 amino acids, atleast 240 amino acids, atleast 255 amino acids, atleast 275 amino acids, atleast 300 amino acids, atleast 329 amino acids, atleast 347 amino acids, atleast 357 amino acids, atleast 371 amino acids, atleast 397 amino acids, atleast 413 amino acids, atleast 432 amino acids, atleast 441 amino acids or atleast 454 amino acids of naturally occurring ANGPTL3 protein. Naturally occurring ANGPTL3 protein according to the present invention includes, but not limited to, human ANGPTL3 protein. In one of the embodiments, the present invention provides the chimeric protein or protein comprising ApoC-III, PCSK-9 and ANGPTL3 wherein the ApoC-III comprises any one of SEQ ID No: 1 or 5; the PCSK-9 comprises any one of SEQ ID No: 2 or 6; and the ANGPTL3 comprises any one of SEQ ID No: 3 or 7. In one of the embodiments, the present invention provides the chimeric protein or protein comprising ApoC-III, PCSK-9 and ANGPTL3 wherein the chimeric protein comprises modification such as insertion, deletion or substitution of atleast one amino acid from atleast any one of said sequences 1 to 7 wherein all or few or any one of said sequences could be codon optimized to improve gene expression leading to increase protein production. In one of the embodiments, the present invention provides the chimeric protein or protein comprising epitopes or mimotopes or fragments encompassing regions between amino acid numbers 16 to 99 of human ApoC-III (SEQ ID No: 1) and fragments encompassing regions between amino acids numbers 150 to 250 of human PCSK9 (SEQ ID No: 2) and fragments encompassing regions between amino acids numbers 15 to 165 of human ANGPTL3 (SEQ ID No: 3). In one embodiment, the chimeric protein or protein of the present invention further comprises an immunogenic carrier. In one of the embodiments, the present invention provides the chimeric protein or protein wherein the chimeric protein or protein is coupled with immunogenic carrier via suitable linker. The immunogenic carrier of the present invention is selected from the group comprising of diphtheria toxin (DT), keyhole limpet haemocyanin (KLH), CRM, such as CRM197, tetanus toxoid (TT), Pan HLA-DR binding epitope (PADRE), virus like particle (VLP), protein D or any other protein or peptide containing helper T-cell epitopes. In one of the embodiments, the present invention provides a chimeric protein wherein the chimeric protein comprising ApoC-III, PCSK9 and ANGPTL3 that are conjugated with suitable immunogenic carriers. In one of the preferred embodiments, the present invention provides the chimeric protein having Formula (II): Universal T cell epitope---L1---ApoC-III---L2---PCSK-9---L2---ANGPTL3---L2---PADRE Formula (II) Wherein, ApoC-III represents Apolipoprotein C-III, PCSK-9 represents proprotein convertase subtilisin / kexin type 9, ANGPTL3 represents Angiopoietin-like protein 3, PADRE represents Pan HLA-DR binding epitope (Universal active peptide that activates T cells) L1 represents Linker 1 and L2 represents Linker 2. In one of the embodiments, the present invention provides a chimeric protein wherein the chimeric protein comprising ApoC-III, PCSK9 and ANGPTL3 that are conjugated with suitable immunogenic carriers, wherein ApoC-III, PCSK9 and ANGPTL3 having amino acid sequences as set forth in SEQ ID No: 1 or 5, SEQ ID No: 2 or 6 and SEQ ID No: 3 or 7 respectively wherein all or few or any one of said sequences could be codon optimized to improve gene expression leading to increase protein production. In one of the embodiments, the present invention provides the chimeric protein comprising ApoC-III, PCSK-9 and ANGPTL3 wherein the chimeric protein comprises modification such as insertion, deletion or substitution of atleast one amino acid from atleast any one of said sequences 1 to 7. In one of the embodiments, the present invention provides the chimeric protein having SEQ ID No: 9. In a further embodiment, the present invention provides a vector comprising gene that encodes the chimeric protein as embodied herein the present invention. In one embodiment, the chimeric protein of the present invention is an immunogen. In one embodiment, the protein of the present invention is an immunogen. In a second embodiment, the present invention provides an immunogenic composition, preferably vaccine comprising the chimeric protein as embodied herein the present invention. In one of the embodiments, the immunogenic composition, preferably vaccine comprises chimeric protein of the present invention and suitable excipients. In one of the embodiments, the immunogenic composition, preferably vaccine comprises chimeric protein of the present invention and suitable excipients wherein the chimeric protein of the present invention is conjugated with a suitable immunogenic carrier. In one of the embodiments, the immunogenic composition, preferably vaccine comprises chimeric protein wherein the chimeric protein comprising ApoC-III and / or PCSK-9 and / or ANGPTL3 are coupled with each other or one another via suitable linker(s). In one of the embodiments, the present invention provides a vaccine composition or immunogenic composition comprising atleast two polypeptide selected from ApoC-III or PCSK9 or ANGPTL3 or any combination thereof and suitable excipients wherein each polypeptide is coupled with immunogenic carrier. In a further embodiment, the present invention relates to a use of the chimeric protein of the present invention as a vaccine or immunogenic composition for the treatment or prevention of diseases mediating through ApoC-III and / or PCSK9 and / or ANGPTL3. In one more embodiment, the immunogen or immunogenic composition or vaccine composition of the present invention can be administered to a subject having, or at risk of having, dyslipidemia and / or atherosclerosis. In one more embodiment, the immunogen or immunogenic composition or vaccine composition of the present invention may be administered alone or co-administered with an additional dyslipidemia therapeutic agent or therapeutic agent that is used in the treatment of atherosclerosis or any other therapeutic agent that is used in the treatment of cardiovascular diseases. Abbreviations used herein the present application The following abbreviations are employed in the examples and elsewhere herein: ANGPTL3: Angiopoietin-like protein 3 ApoC-III: Apolipoprotein C-III DO: Dissolved oxygen DS: Drug substance DV: Diafiltration volume EDTA: Ethylenediaminetetraacetic acid ELISA: Enzyme linked immunosorbent assay IB: Inclusion body o / w: Oil in water emulsion OD: optical density PADRE: Pan HLA-DR binding epitope (Universal active peptide that activates T cells) PCSK-9: Proprotein convertase subtilisin / kexin type 9 PES: Poly ether sulphone RCB vial: Research cell bank or Reference cell bank vial TFF: tangential flow filtration TMB: 3, 3’, 5, 5’ Tetra methyl benzidine Detailed description of the invention The present invention discloses a chimeric protein, composition of chimeric protein, immunogenic compositions of the said chimeric protein, preferably as a vaccine composition and pharmaceutical formulations which comprises the immunogenic composition, preferably a vaccine composition. The chimeric protein of the present invention is an immunogen that induces humoral and / or cellular T cell responses against antigens. The chimeric protein of the present invention includes an ApoC-III or PCSK9 or ANGPTL3 derived peptides or any combination thereof. The chimeric protein of the present invention comprises one or more polypeptides selected from ApoC-III or PCSK9 or ANGPTL3 wherein the said polypeptide(s) is coupled with immunogenic carrier. In one embodiment, present invention provides the chimeric protein wherein the chimeric protein comprising ApoC-III and / or PCSK-9 and / or ANGPTL3 coupled with each other via suitable linker or one another via suitable linker(s) as per Formula (I): Peptide A---L---Peptide B---L---Peptide C Formula (I) Wherein Each of the peptides A or B or C can independently be an Apolipoprotein C-III (ApoC-III) protein or a Proprotein convertase subtilisin / kexin type 9 (PCSK-9) protein or an Angiopoietin- like protein 3 (ANGPTL3) protein, each of which may be optionally mutated with one or more site specific mutations, wherein further each of Peptide A and Peptide C are linked to a suitable immunogenic carrier and wherein further Peptide A, Peptide B and Peptide C does not represent the same peptide ‘L’ at each occurrence may be absent or present and when present, may be same or different and independently represents a linker as defined hereinafter. Linkers are generally comprises of sequences recognized by the proteasome, proteases of the endosomes or other vesicular compartment of the cell. [3] Linker peptides can be synthetic sequences of amino acids that are commonly used to physically connect polypeptide domains. These linker peptides could be composed of repetitive modules of one or more of the amino acids glycine and serine. In one embodiment, linker could be (GGGXX) n, (XGGGS) n, wherein n is greater than or equal to 1 but less than 6, wherein X is any amino acid residue. In one embodiment, linker are 5 amino acid residue glycine-glycine-glycine-glycine-serine (GGGGS) or 15 amino acid residue (GGGGS)3. In another embodiment, the linkers of the present invention could be lysine-arginine (KR), arginine-arginine (RR) or arginine-lysine-arginine (RKR). In other embodiment, inclusion of the linker peptides in polypeptides of the present invention can lead to increased homogeneity, increased pH stability and reduced aggregation. The present invention also discloses a protein that comprises composition of polypeptides selected from ApoC-III or PCSK9 or ANGPTL3. In one embodiment, the protein of the present invention comprises ApoC-III and / or PCSK-9 and / or ANGPTL3 wherein each polypeptide is coupled with immunogenic carrier. The present invention also discloses the protein wherein the protein is combination of atleast two polypeptides selected from ApoC-III and / or PCSK-9 and / or ANGPTL3 wherein each polypeptide is coupled with immunogenic carrier. Here, the protein is a mixture of ApoC-III and / or PCSK-9 and / or ANGPTL3 or any suitable combination thereof. In an embodiment, the ApoC-III according to the present invention comprises amino acid sequence as set forth in SEQ ID No: 1, the PCSK-9 according to the present invention comprises amino acid sequence as set forth in SEQ ID No: 2 and the ANGPTL3 according to the present invention comprises amino acid sequence as set forth in SEQ ID No: 3. In one embodiment, the chimeric protein of the present invention comprises ApoC-III wherein the ApoC-III according to the present invention comprises atleast 2 amino acids, atleast 4 amino acids, atleast 6 amino acids, atleast 8 amino acids, atleast 10 amino acids, atleast 12 amino acids, atleast 14 amino acids, atleast 15 amino acids atleast 19 amino acids, atleast 21 amino acids, atleast 23 amino acids, atleast 26 amino acids, atleast 27 amino acids, atleast 29 amino acids, atleast 32 amino acids, atleast 34 amino acids, atleast 36 amino acids, atleast 39 amino acids, atleast 40 amino acids, atleast 42 amino acids, atleast 44 amino acids, atleast 47 amino acids, atleast 48 amino acids, atleast 52 amino acids, atleast 55 amino acids, atleast 67 amino acids, atleast 77 amino acids, atleast 79 amino acids, atleast 84 amino acids, atleast 95 amino acids or atleast 97 amino acids of the naturally occurring ApoC-III protein. Naturally occurring ApoC-III protein according to the present invention includes, but not limited to, human ApoC-III protein. In one of the embodiments, the chimeric protein or protein of the present invention comprises ApoC-III wherein the ApoC-III comprises 2 to 10 amino acids, 10 to 25 amino acids, 25 to 60 amino acids, 60 to 84 amino acids, 16 to 99 amino acids or 84 to 99 amino acids of SEQ ID No: 1. In one of the embodiments, the chimeric protein or protein of the present invention comprises ApoC-III wherein the ApoC-III comprises any one of SEQ ID No: 1 or 5. In one embodiment, the chimeric protein or protein of the present invention comprises PCSK-9 wherein the PCSK-9 comprises atleast 2 amino acids, atleast 5 amino acids, atleast 7 amino acids, atleast 8 amino acids, atleast 10 amino acids, atleast 13 amino acids, atleast 14 amino acids, atleast 17 amino acids, atleast 18 amino acids, atleast 21 amino acids, atleast 22 amino acids, atleast 24 amino acids, atleast 27 amino acids, atleast 28 amino acids, atleast 30 amino acids, atleast 31 amino acids, atleast 35 amino acids, atleast 37 amino acids, atleast 38 amino acids, atleast 40 amino acids, atleast 42 amino acids, atleast 45 amino acids, atleast 46 amino acids, atleast 48 amino acids, atleast 49 amino acids, atleast 55 amino acids, atleast 60 amino acids, atleast 70 amino acids, atleast 80 amino acids, atleast 85 amino acids, atleast 95 amino acids, atleast 96 amino acids, atleast 100 amino acids, atleast 115 amino acids, atleast 129 amino acids, atleast 157 amino acids, atleast 175 amino acids, atleast 195 amino acids, atleast 220 amino acids, atleast 245 amino acids, atleast 277 amino acids, atleast 310 amino acids, atleast 345 amino acids, atleast 380 amino acids, atleast 390 amino acids, atleast 400 amino acids, atleast 435 amino acids, atleast 455 amino acids, atleast 485 amino acids, atleast 513 amino acids, atleast 537 amino acids, atleast 560 amino acids, atleast 592 amino acids, atleast 617 amino acids, atleast 634 amino acids, atleast 650 amino acids, atleast 670 amino acids, atleast 685 amino acids or atleast 690 amino acids of the naturally occurring PCSK-9 protein. Naturally occurring PCSK-9 protein according to the present invention includes, but not limited to, human PCSK-9 protein. In one of the embodiments, the chimeric protein or protein of the present invention comprises PCSK-9 wherein the PCSK-9 comprises 2 to 10 amino acids, 10 to 25 amino acids, 25 to 60 amino acids, 60 to 85 amino acids, 85 to 100 amino acids, 100 to 200 amino acids, 150 to 250 amino acids, 200 to 350 amino acids, 300 to 400 amino acids or 400 to 650 amino acids of SEQ ID No: 2. In one of the embodiments, the chimeric protein or protein of the present invention comprises PCSK-9 wherein the PCSK-9 comprises any one of SEQ ID No: 2 or 6. In one embodiment, the chimeric protein or protein of the present invention comprises PCSK-9 wherein the PCSK-9 comprises amino acid sequence as set forth in SEQ ID No: 2 or comprising epitopes or mimotopes or fragments of PCSK-9 as set forth in SEQ ID No: 2. In one of the embodiments, the chimeric protein or protein of the present invention comprises ANGPTL3 wherein the ANGPTL3 comprises atleast 2 amino acids, atleast 5 amino acids, atleast 6 amino acids, atleast 8 amino acids, atleast 10 amino acids, atleast 11 amino acids, atleast 17 amino acids, atleast 18 amino acids, atleast 19 amino acids, atleast 20 amino acids, atleast 22 amino acids, atleast 25 amino amino acids, atleast 28 amino acids, atleast 31 amino acids, atleast 32 amino acids, atleast 34 amino acids, atleast 36 amino acids, atleast 39 amino acids, atleast 40 amino acids, atleast 42 amino acids, atleast 45 amino acids, atleast 46 amino acids, atleast 49 amino acids, atleast 50 amino acids, atleast 55 amino acids, atleast 60 amino acids, atleast 70 amino acids, atleast 80 amino acids, atleast 85 amino acids, atleast 95 amino acids, atleast 100 amino acids, atleast 107 amino acids, atleast 115 amino acids, atleast 127 amino acids, atleast 145 amino acids, atleast 153 amino acids, atleast 154 amino acids, atleast 155 amino acids, atleast 179 amino acids atleast 187 amino acids, atleast 207 amino acids, atleast 227 amino acids, atleast 240 amino acids, atleast 255 amino acids, atleast 275 amino acids, atleast 300 amino acids, atleast 329 amino acids, atleast 347 amino acids, atleast 357 amino acids, atleast 371 amino acids, atleast 397 amino acids, atleast 413 amino acids, atleast 432 amino acids, atleast 441 amino acids or atleast 454 amino acids of naturally occurring ANGPTL3 protein. Naturally occurring ANGPTL3 protein according to the present invention includes, but not limited to, human ANGPTL3 protein. In one of the embodiments, the chimeric protein or protein of the present invention comprises ANGPTL3 wherein the ANGPTL3 comprises 2 to 10 amino acids, 10 to 25 amino acids, 25 to 60 amino acids, 60 to 85 amino acids, 85 to 100 amino acids, 15 to 165 amino acids, 100 to 180 amino acids, 183 to 255 a of SEQ ID No: 3. In one of the embodiments, the chimeric protein or protein of the present invention comprises ANGPTL3 wherein the ANGPTL3 comprises any one of SEQ ID No: 3 or 7. In one embodiment, the chimeric protein or protein of the present invention comprises ANGPTL3 wherein the ANGPTL3 comprises amino acid sequence as set forth in SEQ ID No: 3 or comprising epitopes or mimotopes or fragments of ANGPTL3 as set forth in SEQ ID No: 3. In one embodiment, present invention provides a vaccine comprising the polypeptide wherein the polypeptide comprising epitopes or mimotopes or fragments encompassing regions between amino acid numbers 16 to 99 of human ApoC-III (SEQ ID No: 1) and fragments encompassing regions between amino acids numbers 150 to 250 of human PCSK9 (SEQ ID No: 2) and fragments encompassing regions between amino acids numbers 15 to 165 of human ANGPTL3 (SEQ ID No: 3). Epitope is part of antigen molecule to which an antibody attaches itself capable of stimulating immune response. Mimotopes are peptides or proteins that can specifically bind to antibodies and compete with analytes for binding sites by mimicking the structure of epitope. The “fragment” used herein refers to portion of the mentioned peptides or any other antigenic peptide including epitope or mimotopes which is capable to induce the formation of antibodies directed to ApoC-III, PCSK9 and / or ANGPTL3. In one of the embodiments, the chimeric protein or protein of the present invention comprises amino acid sequences as set forth in SEQ ID No: 1, 2, 3, 5, 6, 7 or any combination thereof. In one of the embodiments, the chimeric protein or protein of the present invention comprises amino acid sequences as set forth in SEQ ID No: 1, 2, 3, 5, 6, 7 or any combination thereof wherein the SEQ ID No: 1, 2, 3, 5, 6, 7 comprises modification such as insertion, deletion or substitution of atleast one amino acid. In one of the embodiments, the chimeric protein or protein of the present invention comprises ApoC-III and / or PCSK-9 and / or ANGPTL3 wherein the ApoC-III comprises amino acid sequence as set forth in SEQ ID No: 1 or fragments of ApoC-III, the PCSK-9 comprises amino acid sequence as set forth in SEQ ID No: 2 or fragments of PCSK- 9 and the ANGPTL3 comprises amino acid sequence as set forth in SEQ ID No: 3 or fragments of ANGPTL3. In one of the embodiments, the chimeric protein or protein of the present invention comprising epitopes or mimotopes or fragments encompassing regions between amino acid numbers 16 to 99 of human ApoC-III (SEQ ID No: 1) and fragments encompassing regions between amino acids numbers 150 to 250 of human PCSK9 (SEQ ID No: 2) and fragments encompassing regions between amino acids numbers 15 to 165 of human ANGPTL3 (SEQ ID No: 3). In one embodiment, the chimeric protein or protein of the present invention as embodied here in the present invention comprises immunogenic carrier. The term “immunogenic carrier” as used herein the present invention, refers to materials which have the property of independently eliciting an immunogenic response in-vivo or in-vitro, particularly in subject and which can be covalently coupled to a peptide, polypeptide or protein either directly via formation of peptide or ester bonds between free carboxyl, amino or hydroxyl groups in the peptide, polypeptide or protein and corresponding groups on the immunogenic carrier material, or alternatively by bonding through a conventional bifunctional linking group or as a fusion protein. In one embodiment, the chimeric protein or protein comprises one polypeptide or two polypeptide or three polypeptide selected from ApoC-III, PCSK9 and ANGPTL3 wherein polypeptide is coupled with immunogenic carrier via linker. In one embodiment, the chimeric protein or protein comprises one polypeptide or two polypeptide or three polypeptide selected from ApoC-III, PCSK9 and ANGPTL3 wherein polypeptide is coupled directly with immunogenic carrier without linker. In one embodiment, the chimeric protein comprises an ApoC-III, PCSK9 and ANGPTL3 derived peptides as embodied here in the present invention that are coupled with immunogenic carrier via suitable linker. The chimeric protein coupled with immunogenic carrier so as to improve its immunogenic property and thereby antibody production. These immunogenic carriers like TT (Tetanus toxoid) or cross reactive material 197 (CRM197), a nontoxic diphtheria toxic mutant protein, are used as linkers in vaccines to induce protein specific immune response. KLH is effective carrier protein of numerous epitopes and generates high immune response. Protein D is effective at increasing immunogenicity of vaccines. PADRE is single carrier epitope, a universal synthetic peptide binding MHC-II receptors and activates CD4+T cells, while initiating innate immune response for recombinant vaccines for adjuvant assisted immunization. VLPs is ideal immunogenic carrier assist readily recognised by host immune system. The immunogenic carrier as exemplified here in the present invention are, but not limited to, group consisting of diphtheria toxin (DT), keyhole limpet haemocyanin (KLH), CRM, CRM197 (a nontoxic but antigenically identical variant of diphtheria toxin) other DT point mutants, such as CRM 176, CRM228, CRM 45, CRM 9, CRM 45, CRM 102, CRM 103, CRM 107 and protein D or any other protein or peptide containing helper T-cell epitopes, tetanus toxoid (TT), Pan HLA-DR binding epitope (PADRE), virus like particle (VLP), protein D or any other protein or peptide containing helper T-cell epitopes. In one of the embodiments, the chimeric protein of the present invention comprises ApoC-III and / or PCSK-9 and / or ANGPTL3 wherein the ApoC-III comprises amino acid sequence as set forth in SEQ ID No: 1 or SEQ ID No: 5 or fragments of ApoC-III, the PCSK-9 comprises amino acid sequence as set forth in SEQ ID No: 2 or SEQ ID No: 6 or fragments of PCSK-9 and the ANGPTL3 comprises amino acid sequence as set forth in SEQ ID No: 3 or SEQ ID No: 7 or fragments of ANGPTL3 wherein the chimeric protein comprises immunogenic carrier. In one of the embodiments, the present invention provides the chimeric protein as mentioned in formula (II): Universal T cell epitope---L1---ApoC-III---L2---PCSK-9---L2---ANGPTL3---L2---PADRE Formula (II) Wherein, ApoC-III represents Human Apolipoprotein C-III, PCSK-9 represents Human Proprotein convertase subtilisin / kexin type 9, ANGPTL3 represents Human Angiopoietin-like protein 3, PADRE represents Pan HLA-DR binding epitope (Universal active peptide that activates T cells) L1 represents Linker 1 having amino acid sequence selected from lysine- arginine (KR), arginine-arginine (RR) or arginine-lysine-arginine (RKR) and arginine-arginine (RR) and L2 represents Linker 2 which is one or more of the amino acids glycine and serine selected from (GGGXX) n and (XGGGS) n, wherein n is greater than or equal to 1 but less than 6, preferably GGGGS. The ApoC-III of formula (II) having amino acid sequences as set forth in SEQ ID no: 1 or 5 or any fragments of ApoC-III peptide having atleast 2 amino acid. The PCSK-9 of formula (II) having amino acid sequences as set forth in SEQ ID no: 2 or 6 or any fragments of PCSK-9 peptide having atleast 2 amino acid. The ANGPTL3 of formula (II) having amino acid sequences as set forth in SEQ ID no: 3 or 7 or any fragments of ANGPTL3 peptide having atleast 2 amino acid wherein all or few or anyone of said sequences could be codon optimized to improve gene expression leading to increase protein production. Further, the said amino acid sequences of the present invention comprises modification such as insertion, deletion or substitution of atleast one amino acid. The modification according to the present invention can be substitution or insertion of amino acid with functionally similar amino acids or non-natural amino acids. The universal T- cell epitope of the present invention is one of the immunogenic carrier having SEQ ID No: 4. The universal T-cell epitope of the present invention also includes any fragment of T-cell which possesses antigenic property, or any other epitope of T-cell. The Pan HLA-DR binding epitope (PADRE) is a universal active peptide that activates T cells to generate immunogenic responses. The PADRE according to the present invention having amino acid sequence as set forth in SEQ ID No: 8. The linker 1 and linker 2 of formula (II) can be different or same. The linker 1 and linker 2 can be used interchangeably in the present invention. In one of the embodiments, the chimeric protein according to the present invention is having amino acid sequence as set forth in SEQ ID No: 9. In separate embodiment, the present invention provides a vector comprising gene of interest that encodes chimeric protein of the present invention. The gene of interest can be codon optimized to generate high expression of the chimeric protein of the present invention. The present invention further discloses immunogenic composition, preferably vaccine composition that comprises the chimeric protein as embodied here in the present invention. The chimeric protein or protein as embodied herein the present invention acts as an immunogen that generate immunogenic response and thereby antibody production. The immunogen of the present invention is a chimeric protein that comprises polypeptides selected from ApoC-III, PCSK-9 and ANGPTL3 wherein each polypeptide is coupled with each other via suitable linker. The immunogen of the present invention is a protein that comprises composition or combination of polypeptides selected from ApoC-III, PCSK-9 and ANGPTL3 wherein each polypeptide is coupled with immunogenic carrier. The vaccine of the present invention can be multivalent vaccine comprising peptides ApoC-III, PCSK-9 and ANGPTL3 or fragments thereof as mentioned herein the present invention. In one of the embodiments, the immunogenic composition, preferably vaccine comprising ApoC-III, PCSK-9 and ANGPTL3 or fragments thereof that are coupled together via suitable linker. In further embodiment, the said coupled peptides are linked with immunogenic carrier via suitable linker. In one of the embodiments, the present invention provides a chimeric protein based vaccine that targets ApoC-III, PCSK9 and ANGPTL3 wherein ApoC-III comprises amino acid sequence encompassing within regions between amino acid numbers 16 to 99 of human ApoC-III (SEQ ID No: 1), PCSK9 comprises amino acid sequence encompassing within regions between amino acids numbers 150 to 250 of human PCSK9 (SEQ ID No: 2) and ANGPTL3 comprises amino acid sequence encompassing within regions between amino acids numbers 15 to 165 of human ANGPTL3 (SEQ ID No: 3). In one of the embodiments, the present invention provides a chimeric protein based vaccine that targets ApoC-III, PCSK9 and ANGPTL3 wherein ApoC-III comprises amino acid sequence encompassing within regions between amino acid numbers 1 to 99 of human ApoC-III (SEQ ID No: 1), PCSK9 comprises amino acid sequence encompassing within regions between amino acid numbers 150 to 450 of human PCSK9 (SEQ ID No: 2) and ANGPTL3 comprises amino acid sequence encompassing within regions between amino acid numbers 1 to 250 of human ANGPTL3 (SEQ ID No: 3). In one of the embodiments, the present invention provides a chimeric protein based vaccine that targets ApoC-III, PCSK9 and ANGPTL3 wherein ApoC-III comprises amino acid 1 to 99 of human ApoC-III (SEQ ID No: 1), PCSK9 comprises amino acid 150 to 450 of human PCSK9 (SEQ ID No: 2) and ANGPTL3 comprises amino acid 1 to 250 of human ANGPTL3 (SEQ ID No: 3). In one of the embodiments, the immunogenic composition, preferably vaccine comprising combination of ApoC-III, and / or PCSK-9 and / or ANGPTL3 or fragments thereof. The amino acid sequences of said peptides are mentioned here in table 1. The said peptides also includes full length amino acid sequence of human ApoC-III, human PCSK-9 and human ANGPTL3, fragments there of having atleast 2 amino acid or any other antigenic fragments encompassing amino acid sequence from full length sequences including amino acid sequences as mentioned herein table 1. The disclosed amino acid sequences could be codon optimized to improve gene expression leading to increase protein production. Table 1: Sequence Listing SEQ IDs Sequences 1 MQPRVLLVVALLALLASARASEAEDASLLSFMQGYMKHATKTAKDALSS VQESQVAQQARGWVTDGFSSLKDYWSTVKDKFSEFWDLDPEVRPTSAVA A 2 MGTVSSRRSWWPLPLLLLLLLLLGPAGARAQEDEDGDYEELVLALRSEED GLAEAPEHGTTATFHRCAKDPWRLPGTYVVVLKEETHLSQSERTARRLQA QAARRGYLTKILHVFHGLLPGFLVKMSGDLLELALKLPHVDYIEEDSSVFA QSIPWNLERITPPRYRADEYQPPDGGSLVEVYLLDTSIQSDHREIEGRVMVT DFENVPEEDGTRFHRQASKCDSHGTHLAGVVSGRDAGVAKGASMRSLRV LNCQGKGTVSGTLIGLEFIRKSQLVQPVGPLVVLLPLAGGYSRVLNAACQR LARAGVVLVTAAGNFRDDACLYSPASAPEVITVGATNAQDQPVTLGTLGT NFGRCVDLFAPGEDIIGASSDCSTCFVSQSGTSQAAAHVAGIAAMMLSAEP ELTLAELRQRLIHFSAKDVINEAWFPEDQRVLTPNLVAALPPSTHGAGWQL FCRTVWSAHSGPTRMATAVARCAPDEELLSCSSFSRSGKRRGERMEAQGG KLVCRAHNAFGGEGVYAIARCCLLPQANCSVHTAPPAEASMGTRVHCHQ QGHVLTGCSSHWEVEDLGTHKPPVLRPRGQPNQCVGHREASIHASCCHAP GLECKVKEHGIPAPQEQVTVACEEGWTLTGCSALPGTSHVLGAYAVDNTC VVRSRDVSTTGSTSEGAVTAVAICCRSRHLAQASQELQ 3 MFTIKLLLFIVPLVISSRIDQDNSSFDSLSPEPKSRFAMLDDVKILANGLLQL GHGLKDFVHKTKGQINDIFQKLNIFDQSFYDLSLQTSEIKEEEKELRRTTYK LQVKNEEVKNMSLELNSKLESLLEEKILLQQKVKYLEEQLTNLIQNQPETPE HPEVTSLKTFVEKQDNSIKDLLQTVEDQYKQLNQQHSQIKEIENQLRRTSIQ EPTEISLSSKPRAPRTTPFLQLNEIRNVKHDGIPAECTTIYNRGEHTSGMYAI RPSNSQVFHVYCDVISGSPWTLIQHRIDGSQNFNETWENYKYGFGRLDGEF WLGLEKIYSIVKQSNYVLRIELEDWKDNKHYIEYSFYLGNHETNYTLHLVA ITGNVPNAIPENKDLVFSTWDHKAKGHFNCPEGYSGGWWWHDECGENNL NGKYNKPRAKSKPERRRGLSWKSQNGRLYSIKSTKMLIHPTDSESFE 4 ILMQYIKANSKFIGIPMGLPQSIALSSLMVAQ 5 SEAEDASLLSFMQGYMKHATKTAKDALSSVQESQVAQQARGWVTDGFSS LKDYWSTVKDKFSEFWDLDPEVRPTSAVAA 6 AQSIPWNLERITPPRYRADEYQPPDGGSLVEVYLLDTSIQSDHREIEGRVMV TDFENVPEEDGTRFHRQASKCDSHGTHLAGVVSGRDAGVAKGAS 7 SRIDQDNSSFDSLSPEPKSRFAMLDDVKILANGLLQLGHGLKDFVHKTKGQ INDIFQKLNIFDQSFYDLSLQTSEIKEEEKELRRTTYKLQVKNEEVKNMSLE LNSKLESLLEEKILLQQKVKYLEEQLTNLIQNQPETPEHPEVTSLKTFVEK 8 AKFVAAWTLKAAA 9 ILMQYIKANSKFIGIPMGLPQSIALSSLMVAQRRSEAEDASLLSFMQGYMK HATKTAKDALSSVQESQVAQQARGWVTDGFSSLKDYWSTVKDKFSEFWD LDPEVRPTSAVAAGGGGSAQSIPWNLERITPPRYRADEYQPPDGGSLVEVY LLDTSIQSDHREIEGRVMVTDFENVPEEDGTRFHRQASKCDSHGTHLAGVV SGRDAGVAKGASGGGGSSRIDQDNSSFDSLSPEPKSRFAMLDDVKILANGL LQLGHGLKDFVHKTKGQINDIFQKLNIFDQSFYDLSLQTSEIKEEEKELRRT TYKLQVKNEEVKNMSLELNSKLESLLEEKILLQQKVKYLEEQLTNLIQNQP ETPEHPEVTSLKTFVEKGGGGSAKFVAAWTLKAAA In some embodiments, the immunogen of the present invention include one or more modifications to the amino acid sequence of the base polypeptide fragment. Exemplary amino acids modifications include conservative amino acid substitutions, an addition to the C-terminus of the peptide fragment, and / or an addition to the N-terminus of the peptide fragment. A conservative substitution for an amino acid in peptide of the present invention may be selected from other members of the class to which the amino acid belongs. For example, it is well-known in the art of protein biochemistry that an amino acid belonging to a grouping of amino acids having a particular size or characteristic (such as charge, hydrophobicity and hydrophilicity) can be substituted for another amino acid without altering the activity of a protein, particularly in regions of the protein that are not directly associated with biological activity. The poly peptide of the present invention also can be designed to provide additional sequences, such as, for example, the addition of coding sequences for added C-terminal or N-terminal amino acids that, can, for example, facilitate purification by trapping on columns or use of antibodies. Such tags include, for example, histidine-rich tags that allow purification of polypeptides on nickel columns. Such gene modification techniques and suitable additional sequences are well known in the molecular biology arts. The present invention also describes formulation of the immunogen of the present invention that can be formulated into pharmaceutically acceptable carrier. As used herein, "carrier" includes medium, vehicle, coating, diluent, antibacterial, and / or antifungal agent, isotonic agent, absorption delaying agent, buffer, carrier solution, suspension, colloid, and the like. The use of such media and / or agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions. As used herein, "pharmaceutically acceptable" refers to a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with the immunogen without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. The pharmaceutical composition may be formulated in a variety of forms adapted to a preferred route of administration. Thus, a composition can be administered via known routes including, for example, oral, parenteral (e.g., intradermal, subcutaneous, intramuscular, intravenous, intraperitoneal, etc.). Thus, the immunogen may be provided in any suitable form including but not limited to a solution, a suspension, an emulsion, a spray, an aerosol, or any form of mixture. The formulation may further include one or more additives including such as, for example, an adjuvant, a preservative, an agent that promotes thermostability, a thickener, and the like. A formulation may be conveniently presented in unit dosage form and may be prepared by methods well known in the art of pharmacy. Methods of preparing a composition with a pharmaceutically acceptable carrier include the step of bringing the with a carrier that constitutes one or more accessory ingredients. In one embodiment, the present invention provides vaccine that comprises the chimeric protein as embodied herein the present invention and suitable excipients. In one embodiment, the present invention provides vaccine that comprises the protein as embodied herein the present invention and suitable excipients. The vaccine formulation may comprise of respective carriers, adjuvants, and / or excipients depending on the route of administration. The suitable excipients as exemplified herein the present invention, but not limited to, comprising an adjuvant selected from alum, alum in combination with MF-59, TLR3 agonist selected from Poly(I:C), TLR 4 agonist selected from Monophosphoryl Lipid A or GLA and like, TLR5 agonist selected from Flagellin, TLR7 agonist selected from Gardiquimod and Imiquimod, TLR7 / 8 agonist selected from R848, NOD2 agonist selected from N-glycolyl-MDP, CpG-containing nucleic acid (where the cytosine is unmethylated), QS21 (saponin adjuvant), stable oil in water emulsions like Sepivac SWE™, or any Alum and Oil in water combination or MPL, or stable water in oil emulsion or alum and water in oil combination or any combination thereof that induces both humoral and durable effector T-Cell responses, interleukins, beta-sitosterol and the like. In one embodiment, the present invention provides formulation comprises the chimeric protein as embodied herein the present invention and adjuvant such as alum, oil in water emulsion i.e. Sepivac SWE™. The vaccine or vaccine composition or vaccine formulation can be used interchangeably here in the present invention. In another aspect, this disclosure describes a method of treating a subject having, or at risk of having, dyslipidemia and / or a condition associated with or caused by dyslipidemia (e.g., pancreatitis is associated with high triglyceride levels). Generally, the method includes administering to the subject an effective amount of a pharmaceutical composition that includes the immunogen. The pharmaceutical composition of the present invention includes the chimeric protein, vaccine, vaccine composition or any other immunogenic composition with or without suitable excipients. As used herein, the term "treat" or variations thereof refer to reducing, limiting progression, ameliorating, or resolving, to any extent, the symptoms or signs of dyslipidemia. A "treatment" may be therapeutic or prophylactic. "Therapeutic" and variations thereof refer to a treatment that ameliorates one or more existing symptoms or clinical signs associated with a condition. "Prophylactic" and variations thereof refer to a treatment that limits, to any extent, the development and / or appearance of a symptom or clinical sign of a condition. Generally, a "therapeutic" treatment is initiated after dyslipidemia, atherosclerosis or any other cardiovascular manifests in a subject, while "prophylactic" treatment is initiated before dyslipidemia atherosclerosis or any other cardiovascular manifests in a subject. As used herein, the term "symptom" refers to any subjective evidence of disease or of a patient's condition, while the term "sign" or "clinical sign" refers to an objective physical finding relating to a particular condition capable of being found by one other than the patient. As used herein, the term "ameliorate" refers to any reduction in the extent, severity, frequency, and / or likelihood of a symptom or clinical sign characteristic of dyslipidemia, atherosclerosis or any other cardiovascular diseases. In one embodiment, the present invention provides methods for treating dyslipidaemia, atherosclerosis and other cardiovascular diseases. The methods includes administration of the chimeric protein of the present invention or immunogenic compostions, preferably vaccine to the subject having, or at risk of having, dyslipidemia, atherosclerosis or other cardiovascular diseases. In one of the embodiments, the vaccine of the present invention may be administered subcutaneously, intradermally, intramuscularly, intravenously or any other suitable route. In one of the embodiments of the present invention, the chimeric protein or vaccine of the present invention may be administered alone or co-administered with an additional therapeutic agent, particularly, therapeutic agents that are used in the treatment of dyslipidemia, atherosclerosis or any other cardiovascular diseases. In some embodiments, the additional dyslipidemia therapeutic agent comprises a statin, a bile acid sequestrant, niacin, a fibric acid derivative, and a long chain alpha, omego-dicarboxylic acid or any other therapeutic agent. In some embodiments, the method can include administering sufficient immunogen to provide a minimum dose of at least 10 μg to the subject such as, for example, a dose of at least 25 μg, at least 50 μg, at least 75 μg, at least 100 μg, at least 150 μg, at least 200 μg, or at least 250 μg. The dosage between 10 ug to 1000 ug depending on disease severity and cholesterol levels. Preferably, the dose of vaccine or immunogenic composition according to the present invention is between 25 μg and 100 μg. This range covers all integer and non-integer values between 25 μg and 100 μg. For e.g. it includes 25 μg, 27 μg, 29 μg, 33 μg, 34.5 μg, 37.3 μg, 42.4 μg, 48 μg, 50.9 μg, 53.6 μg, 57.1 μg, 62 μg, 66 μg, 69 μg, 73 μg, 77 μg, 81.3 μg, 85 μg, 87.2 μg, 92.4 μg, 95 μg, 97 μg, 98 μg, 99.3 μg, 100 μg or any integer and non-integer values in between these values. The frequency of administration can vary depending on any of a variety of factors, e.g., severity of the symptoms, degree of immunoprotection desired, whether the composition is used for prophylactic or therapeutic purposes, etc. For example, in some embodiments, the immunogen may be administered once every six months, once per month, twice per month, three times per month, every other week (qow), once per week (qw), twice per week (biw), three times per week (tiw), four times per week, five times per week, six times per week, every other day (qod), daily (qd), twice a day (qid), or three times a day (tid). In some embodiments, the immunogen may be administered from two to four times per year such as, for example, from two to three times per year. When the immunogen is used prophylactically, it can be administered for both priming and boosting doses. Boosting doses can be administered at regular or pre- determined intervals or may be administered as needed— e.g., when the level of circulating antibody falls below a desired level. Boosting doses may include the antigenic polypeptides (ApoC-III, PCSK9 and ANGPTL3) in the absence or presence of the immunogenic carrier molecule. Such booster constructs may include an alternative immunogenic carrier or may be in the absence of any carrier. Such booster compositions may be formulated with adjuvant. These chimeric vaccine or individual subunit vaccine or combination of polypeptides comprising of ApoC-III, PCSK-9 and ANGPTL-III will be useful in treatment or prevention of diseases mediating through ApoC-III, PCSK-9 and ANGPTL-3 and are capable of inducing the formation of antibodies directed against these polypeptides in vivo. The vaccine strategy according to the present invention, is inventive to existing biologics or anti-sense oligonucleotide based inhibitions as therapeutic or prophylactic for dyslipidaemia. In the preceding description, the term “peptide” and “polypeptide” can be used interchangeably. In the preceding description, the term "and / or" means one or all of the listed elements or a combination of any two or more of the listed elements; the terms "comprises," "comprising," and variations thereof are to be construed as open ended— i.e., additional elements or steps are optional and may or may not be present; unless otherwise specified, "a," "an," "the," and "at least one" are used interchangeably and mean one or more than one; and the recitations of numerical ranges by endpoints include all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.). In the preceding description, particular embodiments may be described in isolation for clarity. Unless otherwise expressly specified that the features of a particular embodiment are incompatible with the features of another embodiment, certain embodiments can include a combination of compatible features described herein in connection with one or more embodiments. For any method disclosed herein that includes discrete steps, the steps may be conducted in any feasible order. And, as appropriate, any combination of two or more steps may be conducted simultaneously. The present invention is illustrated by the following examples. It is to be understood that the particular examples, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein. Preferred embodiments of the present invention In one embodiment, the present invention provides a chimeric protein comprising polypeptides ApoC-III, PCSK-9 and ANGPTL3, wherein the ApoC-III, PCSK-9 and ANGPTL3 are coupled with each other via one or more suitable linker(s) as per Formula (I): Peptide A---L---Peptide B---L---Peptide C Formula (I) Wherein, the Peptide A, Peptide B and Peptide C represents any of ApoC-III or PCSK-9 or ANGPTL3 polypeptide and wherein further each of Peptide A and Peptide C are linked to a suitable immunogenic carrier and wherein further Peptide A, Peptide B and Peptide C does not represent the same peptide and wherein L represents a suitable linker. In one embodiment, the present invention provides, the chimeric protein as embodied in herein the present invention, wherein the immunogenic carrier is selected from the group consisting of diphtheria toxin (DT), keyhole limpet haemocyanin (KLH), CRM, preferably CRM197, a tetanus toxoid (TT), Pan HLA-DR binding epitope (PADRE), universal T cell epitope) Protein D or any other protein or peptide containing helper T-cell epitopes. In one embodiment, the present invention provides, the chimeric protein as embodied in herein the present invention, wherein the linker L comprises group of peptides selected from glycine- glycine-glycine-glycine-serine (GGGGS) or 15 amino acid residue (GGGGS)3, lysine-arginine (KR), arginine-arginine (RR) or arginine-lysine-arginine (RKR). In one embodiment, the present invention provides, the chimeric protein as embodied in herein the present invention, wherein chimeric protein is according to Formula (II): Universal T cell epitope---L1---ApoC-III---L2---PCSK-9---L2---ANGPTL3---L2---PADRE Formula (II) Wherein, ApoC-III represents Human Apolipoprotein C-III, PCSK-9 represents Human Proprotein convertase subtilisin / kexin type 9, ANGPTL3 represents Human Angiopoietin-like protein 3, PADRE represents Pan HLA-DR binding epitope (Universal active peptide that activates T cells) L1 represents Linker 1 having amino acid sequence selected from lysine- arginine (KR), arginine-arginine (RR) or arginine-lysine-arginine (RKR) and arginine-arginine (RR) and L2 represents Linker 2 which is one or more of the amino acids glycine and serine selected from (GGGXX) n and (XGGGS) n, wherein n is greater than or equal to 1 but less than 6 wherein XX represents any amino acid residue, preferably GGGGS. In one embodiment, the present invention provides, the chimeric protein as embodied in herein the present invention, wherein the ApoC-III comprises amino acids sequence as set forth in SEQ ID No 1 or 5. In one embodiment, the present invention provides, the chimeric protein as embodied in herein the present invention, wherein the ApoC-III comprises 2 to 10 amino acids, 10 to 25 amino acids, 25 to 60 amino acids, 60 to 84 amino acids, 16 to 99 amino acids or 84 to 99 amino acids of SEQ ID No 1 or 5. In one embodiment, the present invention provides, the chimeric protein as embodied in herein the present invention, wherein the PCSK-9 comprises amino acids sequences as set forth in SEQ ID No 2 or 6. In one embodiment, the present invention provides, the chimeric protein as embodied in herein the present invention, wherein the PCSK-9 comprises 2 to 10 amino acids, 10 to 25 amino acids, 25 to 60 amino acids, 60 to 85 amino acids, 85 to 100 amino acids, 100 to 200 amino acids, 150 to 250 amino acids, 200 to 350 amino acids, 300 to 400 amino acids or 400 to 650 amino acids of SEQ ID No 2 or 6. In one embodiment, the present invention provides, the chimeric protein as embodied in herein the present invention, wherein the ANGPTL3 comprises amino acids sequence as set forth in SEQ ID No 3 or 7. In one embodiment, the present invention provides, the chimeric protein as embodied in herein the present invention, wherein the ANGPTL3 comprises 2 to 10 amino acids, 10 to 25 amino acids, 25 to 60 amino acids, 60 to 85 amino acids, 85 to 100 amino acids, 15 to 165 amino acids or 100 to 180 amino acids of SEQ ID No 3 or 7. In one embodiment, the present invention provides, the chimeric protein as embodied in herein the present invention, wherein the ApoC-III comprises any one of SEQ ID No: 1 or 5; the PCSK- 9 comprises any one of SEQ ID No: 2 or 6; and the ANGPTL3 comprises any one of SEQ ID No: 3 or 7 or any modification such as insertion, deletion or substitution of atleast one amino acid from said sequences. In one embodiment, the present invention provides, the chimeric protein as embodied herein the present invention, comprising epitopes or mimotopes or fragments encompassing regions between amino acid numbers 16 to 99 of human ApoC-III (SEQ ID No: 5) and fragments encompassing regions between amino acids numbers 150 to 250 of human PCSK9 (SEQ ID No: 6) and fragments encompassing regions between amino acids numbers 15 to 165 of human ANGPTL3 (SEQ ID No: 7). In one embodiment, the present invention provides, the chimeric protein as embodied herein the present invention, wherein the chimeric protein comprising ApoC-III, PCSK9 and ANGPTL3 that are conjugated with suitable immunogenic carriers wherein ApoC-III, PCSK9 and ANGPTL3 having amino acid sequences as set forth in SEQ ID No: 5, SEQ ID No: 6 and SEQ ID No: 7 respectively. In one embodiment, the present invention provides, the chimeric protein as embodied herein the present invention, wherein the immunogenic carriers are universal T cell epitope having SEQ ID No: 4 and Pan HLA-DR binding epitope (PADRE) having SEQ ID No: 8. In one embodiment, the present invention provides, the chimeric protein as embodied herein the present invention, comprises amino acid sequence as set forth in SEQ ID No: 9. In one embodiment, the present invention provides, a vector comprising gene encoding the chimeric protein as embodied herein the present invention. In one embodiment, the present invention provides, the chimeric protein as embodied herein the present invention, wherein the chimeric protein is an immunogen. In one embodiment, the present invention provides, the immunogenic composition, preferably vaccine comprising the chimeric protein as embodied herein the present invention and suitable excipients. In one embodiment, the present invention provides, the immunogenic composition, preferably vaccine as embodied herein the present invention, wherein the suitable excipients comprising an adjuvant selected from alum, alum in combination with MF-59, TLR3 agonist selected from Poly(I:C), TLR 4 agonist selected from Monophosphoryl Lipid A or GLA and like, TLR5 agonist selected from Flagellin, TLR7 agonist selected from Gardiquimod and Imiquimod, TLR7 / 8 agonist selected from R848, NOD2 agonist selected from N-glycolyl-MDP, CpG- containing nucleic acid, QS21, stable oil in water emulsions Sepivac SWE™ or any Alum and Oil in water combination or MPL, or stable water in oil emulsion or alum and water in oil combination or any combination thereof inducing both humoral and durable effector T-Cell responses, interleukins, beta-sitosterol and the like. In one embodiment, the present invention provides, a protein comprising polypeptides wherein the polypeptide is selected from ApoC-III or PCSK-9 or ANGPTL3 or any combination thereof wherein each polypeptide is coupled with immunogenic carrier. In one embodiment, the present invention provides, the protein as embodied herein the present invention, wherein the immunogenic carrier is selected from the group consisting of diphtheria toxin (DT), keyhole limpet haemocyanin (KLH), CRM, preferably CRM197, tetanus toxoid (TT), Pan HLA-DR binding epitope (PADRE), universal T cell epitope, virus like particle (VLP) or any other protein or peptide containing helper T-cell epitopes. In one embodiment, the present invention provides, the protein as embodied herein the present invention, wherein ApoC-III comprises any amino acid sequences as embodied herein the present invention. In one embodiment, the present invention provides, the protein as embodied herein the present invention, wherein PCSK-9 comprises any amino acid sequences as embodied herein the present invention. In one embodiment, the present invention provides, the protein as embodied herein the present invention, wherein ANGPTL3 comprises any amino acid sequences as embodied herein the present invention. In one embodiment, the present invention provides, the protein as embodied herein the present invention, wherein the immunogenic carriers are universal T cell epitope having SEQ ID No: 4 and Pan HLA-DR binding epitope (PADRE) having SEQ ID No: 8. In one embodiment, the present invention provides, the protein as embodied herein the present invention, wherein the protein is an immunogen. In one embodiment, the present invention provides, the immunogenic composition, preferably vaccine comprising the protein as embodied herein the present invention and suitable excipients as embodied herein the present invention. In one embodiment, the present invention provides, the immunogenic composition, preferably vaccine as embodied herein the present invention used in the treatment of diseases mediating through ApoC-III and / or PCSK9 and / or ANGPTL3. In one embodiment, the present invention provides, the immunogenic composition, preferably vaccine as embodied herein the present invention used in the treatment of dyslipidemia and / or atherosclerosis and / or any cardiovascular disease. In one embodiment, the present invention provides, the immunogenic composition, preferably vaccine as embodied herein the present invention, administered alone or co-administered with an additional dyslipidemia therapeutic agent or therapeutic agent that is used in the treatment of atherosclerosis. In one embodiment, the present invention provides, the immunogenic composition, preferably vaccine as embodied herein the present invention, wherein the said vaccine is administered in a subject at dose between 10 µg and 1000 µg, preferably between 25 µg and 100 µg. In one embodiment, the present invention provides, the protein or immunogenic composition, vaccine or vaccine combination selected from ApoC-III and / or PCSK9 and / or ANGPTL3 or any combination thereof, preferably vaccine as embodied herein the present invention, used in the treatment of diseases mediating through ApoC-III and / or PCSK9 and / or ANGPTL3. In one embodiment, the present invention provides, the protein or immunogenic composition, vaccine or vaccine combination selected from ApoC-III and / or PCSK9 and / or ANGPTL3 or any combination thereof, preferably vaccine as administered alone or co-administered with an additional dyslipidemia therapeutic agent or therapeutic agent that is used in the treatment of dyslipidemia as embodied herein the present invention used in the treatment of dyslipidemia and / or atherosclerosis and / or any cardiovascular disease. Examples Example 1: Preparation of vaccine comprising ApoC-III, PCSK-9 and ANGPTL3 (drug substance) Clone development The can be produced in microorganisms such as bacteria such as E.coli, B. subtilis, or any other bacterium that is capable of expressing such peptides, yeast such as Saccharomyces cerevisiae, Schizosaccharomyces pombe, Candida albicans, Pichia pastoris or any other yeast capable of expressing peptides, in eukaryotic cells such as mammalian or insect cells, or in a recombinant virus vector such as adenovirus, poxvirus, herpes virus, Simliki forest virus, baculovirus, bacteriophage, sindbis virus or Sendai virus. The nucleotide sequence herein the present invention was codon optimized and synthesized by GeneScript (Singapore). BLR 21 (DE3) E.coli cells were used. Various bacterial expression system such as pBluescript II, pET, pGEX, pMAL, pQE, pGS etc can be used to express gene of interest. Cloning and expression of gene of interest is a very well-known technique available in the art [Molecular cloning: A Laboratory Manual by Sambrook et.al (2001)] for a skilled person. Figure 1 and Figure 2 of the present invention demonstrate the expression vector with multiple cloning sites (MCS) i.e. pET30a (+). This is a 5.3 kb vector used to express recombinant proteins in Escherichia coli. It is a T7 promoter driven expression system that allows inducible, high level expression of the gene of interest in E.coli. The vector consists of Kanamycin resistance gene, which allows selection of transformants in E.coli and a F1 origin, which allows replication and maintenance of the plasmid in E.coli. The gene was cloned between NdeI and BamHI, restriction sites of this vector as highlighted in Figure 1. Glycerol stocks preparation: Glycerol stock (RCB vial) was prepared by inoculating 1 ml of culture from research cell bank to defined media as per the methods outlined in book Molecular cloning: A Laboratory Manual by Sambrook et.al. Cell revival and fermentation: 1 ml of RCB vial culture was revived in 200 ml of complex media and incubated at 37 ± 2 °C with shaking at 200 rpm till OD was reached ≥ 3.0. Once OD was achieved, 5 % of pre seed culture was transferred to 500 ml of seed flask at 37 ± 2 °C with shaking at 200 rpm till OD was reached ≥ 3.0. Once OD was reached > 3.0, 500 ml of matured seed culture was transferred to fermenter having 10 litres of complex media. Fermentation was carried out at 37 ± 2 °C with agitation speed of 300-900 rpm, pH 6.8 ± 2 and DO maintaining at 40 %. Once desired OD was achieved, the fermentation broth was induced with 1M IPTG to get final concentration of 1 mM. Induction was kept for 2 hours and fermenter broth was harvested and centrifuged to obtained cell pellet. Cell pellet was stored at below -70 °C till further use. Process flow of preparing drug substance: The cell pellet was prepared as per procedure mentioned herein above. The process of preparing drug substance has been described herein below. Flow chart has been depicted in Figure 3 of current specification. Cell lysis: The cell harvest pellet was suspended in lysis buffer (20 mM Tris, pH 7.5) with ratio of buffer to pellet 1:4 w / v (i.e. for 20 gm pellet add 80 ml buffer). Cell lysis was performed using high pressure homogenizer for 2 cycles at 16 Kpsi pressure. Centrifugation and IB washing: Centrifuge at 10000 rpm for 45min, retain pellet for processing and discard supernatant. Resuspend pellet in WFI, with ratio WFI to harvest pellet 1:3 w / v (i.e. For 20 gm pellet add 60 ml WFI). Solubilization: Solubilize IB in solubilization buffer (20 mM Tris + 6M Urea pH 7.5), with ratio of buffer to harvest pellet 1:5 w / v (i.e. for 20 gm pellet add 100 ml buffer), and kept on stirring for 1 hr. at room temperature. Anion exchange (AEX) chromatography: Perform AEX chromatography using fractogel DEAE resin and collect fractions using linear gradient with following parameters. o Residence time: about 5 min o Bed Height: about 10 cm o Equilibration buffer: 20mM Tris+6M Urea pH 7.0 o Elution buffer: 20mMTris+6MUrea+1MNaCLpH 7.0 However, further chromatography methods well known in the art like gel filtration, affinity chromatography etc can be used for isolating and purifying recombinant produced chimeric protein of the present invention. Refolding: based on purity and dilute in refolding buffer (0.75M L-arginine, 20 mM Tris, 5 mM EDTA, 0.01% Tween 80, pH 7.5) with ratio of buffer to harvest pellet 1:25 w / v (i.e. for 20 gm pellet add 500 ml buffer). Incubate at 2-8 °C for more 4 hrs to overnight. Concentration and Dia-filtration (TFF): Concentrate to about 5x of initial volume and perform 15 DV dia-filtration with drug substance (DS) buffer (50 mM citrate phosphate, 0.150 M NaCl, 0.01% Tween 80, 50 mM L-Arginine pH 7.5.) Sterile filtration: Performed filtration using 0.2µ PES filter. Example 2: Preparation and formulation of vaccine comprising human ApoC-III, human PCSK-9 and human ANGPTL3 with suitable excipients (drug product) Vaccine formulation can be prepared by using various adjuvants such as alum, alum in combination with MF-59, TLR3 agonist selected from Poly(I:C), TLR 4 agonist selected from Monophosphoryl Lipid A or GLA and like, TLR5 agonist selected from Flagellin, TLR7 agonist selected from Gardiquimod and Imiquimod, TLR7 / 8 agonist selected from R848, NOD2 agonist selected from N-glycolyl-MDP, CpG-containing nucleic acid (where the cytosine is unmethylated), QS21 (saponin adjuvant), stable oil in water emulsions or water in oil emulsion inducing both humoral and durable effector T-Cell responses such as Sepivac SWE™, interleukins, beta-sitosterol and the like to a drug substance of the present invention. The present example describes the formulation of vaccine comprising different immunogenic epitopes with alum and seppic emulsion adjuvant as prepared herein below: The required quantity of SEPIVAC SWETM o / w nano-emulsion adjuvant was first dispensed in the formulation container. To it, required quantity of aluminium hydroxide gel (alum) was added dropwise with continuous stirring to form an intermediate aluminium nano-emulsion adjuvant. Now required quantity of drug substance (SFB) was added dropwise with continuous stirring aseptically. The table 2 shows various formulations and dosage as prepared by current method described here. This method enables antigen of drug substance loading onto aluminium hydroxide by electrostatic interaction. Finally, required amount of diluent was added to the formulation container to complete the formulation. The formulated bulk is incubated overnight at 2-8 °C under stirring for complete adsorption. Next day, formulation was ready for testing / immunization. Table 2: Vaccine formulation comprising ApoC-III, PCSK-9 and ANGPTL3 (drug substance) with alum formulation for immunogenicity studies Formulation Drug substance 50 µg / dose Alum 0.5 mg / dose Dosage 1.0 ml NA: Not available Purification of drug product SDS-PAGE has been carried out for drug product i.e. chimeric ApoC-III protein against marker (M) protein. The result has been described in Figure 4. Example 3: Analysis of antibody response by ELISA Animal dosing: The purified chimeric protein was formulated and injected in animals at different dose and regimen. For eg. : 2 Dose (50 mcg and 100 mcg) at Day 0, 14 or 28 or 42 or 56. Purified chimeric protein was formulated in the presence of aluminum hydroxide gel (alum) as shown in table 2. The concentration of chimeric protein and alum has been as mentioned in table 2. Buffer was used as diluent to make up the final formulation volume. Animals were bled on each interval (for eg. Day 0, 14, 21, 28, 42, 56 etc.,) and antibody titre has been analyzed from blood serum of animals against total chimeric antigen (multimeric protein containing ApoC-III, PCSK9 and ANGPTL3), ApoC-III specific protein, PCSK9 protein and ANGPTL3 protein by ELISA as shown in Figure 5. ELISA Indirect ELISA was performed against each antigen (ApoC-III, PCSK9 and ANGPTL3) as mentioned below and its endpoint titers were calculated and plotted in the Figure 6a, Figure 6b to Figure 16. An indirect ELISA was used to measure IgG antibodies present in the animal sera samples post vaccination with chimeric vaccine. In brief, recombinant chimeric ApoC-III protein antigen was coated onto a 96 well microplate followed by overnight incubation at 2-8 °C. Next day, the plate was washed with the washing buffer and blocking solution was added for 1 hour at 35 ± 2 °C. Again, plate was washed using washing buffer and then animal sera samples were added at required dilutions to the plate. Plate was further incubated for 1 hour at 35 ± 2 °C followed by washing with washing buffer. After that, secondary antibody was added at appropriate dilution and plate was incubated again for 1 hour at 35 ± 2 °C followed by washing with washing buffer. Then 3,3’,5,5’Tetramethyl benzidine (TMB) substrate was added and plate was covered with aluminium foil and incubated for 10 to 15 minutes at room temperature. After that stop solution was added to stop the enzyme substrate reaction. Plate absorbance was recorded using microplate reader using molecular devices at 450 nm. The ELISA unit (EU) were calculated through the four parametric curve fit using the microplate reader software (SoftMax Pro). Immunogenicity studies evaluated with multimeric polypeptide showed good immunogenic response at Day 28, 42, 56, 70 and 84, while placebo show no immunogenic response as mentioned in Figure 6a and Figure 6 B. Further, immunogenic response in mice with specific ApoC-III protein antigen show good immunogenic response up to Day 70, while placebo has minimal response as mentioned in Figure 7. In addition, immunogenic response in mice with specific PCSK-9 specific protein antigen show good immunogenic response up to Day 70, while placebo has minimal response as mentioned in Figure 8. Furthermore, immunogenic response in mice with specific ANGPTL-3 specific protein antigen show good immunogenic response up to Day 70, while placebo has minimal response as mentioned in Figure 9. Similarly without -his tag chimeric protein immunogenic response in BALB / c mice with dosing at Day 0, Day 28, and Day 84 (Immunogenicity study is shown in Figure 10) was evaluated, and good immunogenic response was observed against individual protein component of chimeric vaccine in ELISA. Graphical representation of immunogenicity study results are shown in Figure 11. To investigate immune response against individual protein, another ELISA was performed separately using ApoC-III, PCSK-9 and ANGPTL-III. Immunogenic response in mice with specific ApoC-III protein antigen is graphically represented in Figure 12. Similarly immunogenic response in mice with specific human PCSK-9 protein antigen is represented in Figure 13 and Immunogenic response in mice with specific human ANGPTL-3 protein antigen in Figure 14. These data demonstrate significant immunogenic response of all three proteins in in BALB / c mice. Example 4: Immunogenicity study evaluated with alum together with Seppic SWETM oil in water (o / w) adjuvant Purified chimeric protein was formulated in the presence of aluminum hydroxide gel (alum) and Seppic oil in water with a concentration / dose as shown in below table 3 and the concentration of alum was 0.5 mg / dose. Buffer was used as diluent to make up the final formulation volume. Immunogenic response has been evaluated in Day 14 and data has been mentioned in Figure 17. Table 3: Formulation of chimeric protein with alum and oil in water Sr. Group Details Dose Route of No Immunization 1 PBS animal (s.c.) NA 2 Placebo for alum + Oil in water emulsion NA (s.c.) S.C. 3 Alum formulation + Oil in water emulsion 50 µg 4 Alum formulation + Oil in water emulsion 100 µg 5 Placebo for oil in water emulsion NA NA: Not available; S.C.: subcutaneous Immunogenic response in mice immunized with Alum + oil in water emulsion (Seppic SWETM adjuvant) showed enhanced antibody titre while placebo showed negligible immunogenic response. Example 5: Immunogenicity study of chimeric vaccine with dual adjuvant system in BALB / c mice. Immunogenicity study of vaccine in BALB / c mice-with combination adjuvant (o / w + Alum) with individual antigens resulted in better immunogenic response towards all the three antigens compared to Alum alone as described in Figure 18A (ApoC-III), Figure 18B (PCSK-9), Figure 18C (ANGPTL-3). This longevity data of immune response till 140 days might be translated into durable clinical response in human clinical studies. Example 6: Immunogenicity study of chimeric vaccine with dual adjuvant system in Zucker fa / fa Rat. Zucker fa / fa rats were immunized thrice at intervals of Day 0, Day 28 and Day 84 and serum was collected at different time points. Immunogenicity of each component of chimeric protein ApoC- III, PCSK-9 and ANGPTL-3 was analyzed by ELISA. As shown in Figure 19A (ApoC-III), Figure 19B (PCSK-9) and Figure 19C (ANGPTL-3). Significant antibody titers were observed with vaccine formulated in dual adjuvant system. This longevity study results with sustained immune response till 6 months, might be translated in significant durable immune response in human clinical studies. The Effectiveness of vaccine in elderly has been another area of concern, this study results shows that vaccine based treatment strategy is feasible for diseases such as familial dyslipidemia, which are otherwise very expensive and unrealistic for use by lifelong administration of biologics at very regular intervals. Example 7: Binding assay of PCSK-9 protein with sera of vaccinated Zucker fa / fa rats Serum of chimeric vaccine immunized with PCSK-9 vaccine was collected at Day 84 (11 weeks after 1st vaccination) and analysis of binding assay was performed with PCSK-9 protein by Surface Plasmon resonance (SPR). The SPR data shows significant binding to PCSK-9 protein as described in Figure 20 which suggests that the chimeric vaccine could generate significant amount of functional antibody post immunization. Example 8: Analysis of Immunogenicity in PCSK9 vaccinated C57BL / 6 mice fed on high fat diet in a two dose study The present example describes the Immunogenicity of vaccine in C57BL / 6J mice fed on high fat diet post vaccination of PCSK-9 formulation of vaccine comprising PSCK-9 with alum and Oil in water adjuvant. High circulating antibody titers measured for PCSK-9 each of individual proteins as described in (Figure 21), PCSK-9 vaccine also elicits a dose dependent response with highest response about 100 µg after 2 doses. These high antibody titer, are likely to reduce triglyceride and cholesterol in animal studies and hence expected in the treatment of dyslipidemia and atherosclerosis. As individual antigen of PCSK-9 reflected good immune response, a combination vaccine comprising individual antigens of ApoC-III, PCSK-9 and ANGPTL3 is a effective vaccine for dyslipidemia. Individual proteins for preparing the combination vaccine were expressed and purified as described in example 1. A combination vaccine in different ratios of ApoC-III, PCSK-9 and ANGPTL-III or individual protein vaccine comprising of ApoC-III, PCSK-9 and ANGPTL-III prepared which provides significant results of efficacy and immunogenicity in- vitro and in-vivo and it is useful in treatment or prevention of diseases mediating through ApoC- III, PCSK-9 or ANGPTL-3. Incorporation by reference The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes. Equivalents The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein. References 1. NORATA G.D. ET AL.: "Apolipoprotein C-III: from pathophysiology to pharmacology", TRENDS IN PHARMACOLOGICAL SCIENCES, vol.36, no.10, 2015, pages 675 – 687. 2. SAHEBKAR A. ET AL.: "Recent advances in pharmacotherapy for hypertriglyceridemia", PROGRESS IN LIPID RESEARCH. vol.56, 2014, pages 47 – 66. 3. WO2021001804 titled “ANGPTL3 based vaccine for the treatment of liver disease” published on Jan 07, 2021. 4. Sambrook et.al : “Molecular cloning: A Laboratory Manual”
[0002] ZLL-PCT0895_ST25 SEQUENCE LISTING <110> ZYDUS LIFESCIENCES LIMITED <120> Protein based chimeric vaccine for dyslipidemia & atherosclerosis <130> ZLL-PCT0895 <150> 202321036282 <151> 2023-05-25 <160> 9 <170> PatentIn version 3.5 <210> 1 <211> 99 <212> PRT <213> human apolipoprotein C-III (ApoC-III). <400> 1 Met Gln Pro Arg Val Leu Leu Val Val Ala Leu Leu Ala Leu Leu Ala 1 5 10 15 Ser Ala Arg Ala Ser Glu Ala Glu Asp Ala Ser Leu Leu Ser Phe Met 20 25 30 Gln Gly Tyr Met Lys His Ala Thr Lys Thr Ala Lys Asp Ala Leu Ser 35 40 45 Ser Val Gln Glu Ser Gln Val Ala Gln Gln Ala Arg Gly Trp Val Thr 50 55 60 Asp Gly Phe Ser Ser Leu Lys Asp Tyr Trp Ser Thr Val Lys Asp Lys 65 70 75 80 Phe Ser Glu Phe Trp Asp Leu Asp Pro Glu Val Arg Pro Thr Ser Ala 85 90 95 Val Ala Ala <210> 2 <211> 692 <212> PRT <213> human proprotein convertase subtilisin / kexin type 9 (PCSK-9) <400> 2 Met Gly Thr Val Ser Ser Arg Arg Ser Trp Trp Pro Leu Pro Leu Leu 1 5 10 15 Leu Leu Leu Leu Leu Leu Leu Gly Pro Ala Gly Ala Arg Ala Gln Glu 20 25 30 Asp Glu Asp Gly Asp Tyr Glu Glu Leu Val Leu Ala Leu Arg Ser Glu 35 40 45 Page 1 ZLL-PCT0895_ST25 Glu Asp Gly Leu Ala Glu Ala Pro Glu His Gly Thr Thr Ala Thr Phe 50 55 60 His Arg Cys Ala Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr Val Val 65 70 75 80 Val Leu Lys Glu Glu Thr His Leu Ser Gln Ser Glu Arg Thr Ala Arg 85 90 95 Arg Leu Gln Ala Gln Ala Ala Arg Arg Gly Tyr Leu Thr Lys Ile Leu 100 105 110 His Val Phe His Gly Leu Leu Pro Gly Phe Leu Val Lys Met Ser Gly 115 120 125 Asp Leu Leu Glu Leu Ala Leu Lys Leu Pro His Val Asp Tyr Ile Glu 130 135 140 Glu Asp Ser Ser Val Phe Ala Gln Ser Ile Pro Trp Asn Leu Glu Arg 145 150 155 160 Ile Thr Pro Pro Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro Asp Gly 165 170 175 Gly Ser Leu Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Asp 180 185 190 His Arg Glu Ile Glu Gly Arg Val Met Val Thr Asp Phe Glu Asn Val 195 200 205 Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys Cys Asp 210 215 220 Ser His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly 225 230 235 240 Val Ala Lys Gly Ala Ser Met Arg Ser Leu Arg Val Leu Asn Cys Gln 245 250 255 Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe Ile Arg 260 265 270 Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu Leu Pro 275 280 285 Leu Ala Gly Gly Tyr Ser Arg Val Leu Asn Ala Ala Cys Gln Arg Leu 290 295 300 Ala Arg Ala Gly Val Val Leu Val Thr Ala Ala Gly Asn Phe Arg Asp 305 310 315 320 Page 2 ZLL-PCT0895_ST25 Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val Ile Thr Val 325 330 335 Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr Leu Gly 340 345 350 Thr Asn Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly Glu Asp Ile 355 360 365 Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Val Ser Gln Ser Gly 370 375 380 Thr Ser Gln Ala Ala Ala His Val Ala Gly Ile Ala Ala Met Met Leu 385 390 395 400 Ser Ala Glu Pro Glu Leu Thr Leu Ala Glu Leu Arg Gln Arg Leu Ile 405 410 415 His Phe Ser Ala Lys Asp Val Ile Asn Glu Ala Trp Phe Pro Glu Asp 420 425 430 Gln Arg Val Leu Thr Pro Asn Leu Val Ala Ala Leu Pro Pro Ser Thr 435 440 445 His Gly Ala Gly Trp Gln Leu Phe Cys Arg Thr Val Trp Ser Ala His 450 455 460 Ser Gly Pro Thr Arg Met Ala Thr Ala Val Ala Arg Cys Ala Pro Asp 465 470 475 480 Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys Arg Arg 485 490 495 Gly Glu Arg Met Glu Ala Gln Gly Gly Lys Leu Val Cys Arg Ala His 500 505 510 Asn Ala Phe Gly Gly Glu Gly Val Tyr Ala Ile Ala Arg Cys Cys Leu 515 520 525 Leu Pro Gln Ala Asn Cys Ser Val His Thr Ala Pro Pro Ala Glu Ala 530 535 540 Ser Met Gly Thr Arg Val His Cys His Gln Gln Gly His Val Leu Thr 545 550 555 560 Gly Cys Ser Ser His Trp Glu Val Glu Asp Leu Gly Thr His Lys Pro 565 570 575 Pro Val Leu Arg Pro Arg Gly Gln Pro Asn Gln Cys Val Gly His Arg 580 585 590 Page 3 ZLL-PCT0895_ST25 Glu Ala Ser Ile His Ala Ser Cys Cys His Ala Pro Gly Leu Glu Cys 595 600 605 Lys Val Lys Glu His Gly Ile Pro Ala Pro Gln Glu Gln Val Thr Val 610 615 620 Ala Cys Glu Glu Gly Trp Thr Leu Thr Gly Cys Ser Ala Leu Pro Gly 625 630 635 640 Thr Ser His Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys Val Val 645 650 655 Arg Ser Arg Asp Val Ser Thr Thr Gly Ser Thr Ser Glu Gly Ala Val 660 665 670 Thr Ala Val Ala Ile Cys Cys Arg Ser Arg His Leu Ala Gln Ala Ser 675 680 685 Gln Glu Leu Gln 690 <210> 3 <211> 460 <212> PRT <213> human angiopoietin-related protein 3 preproprotein (ANGPTL3) <400> 3 Met Phe Thr Ile Lys Leu Leu Leu Phe Ile Val Pro Leu Val Ile Ser 1 5 10 15 Ser Arg Ile Asp Gln Asp Asn Ser Ser Phe Asp Ser Leu Ser Pro Glu 20 25 30 Pro Lys Ser Arg Phe Ala Met Leu Asp Asp Val Lys Ile Leu Ala Asn 35 40 45 Gly Leu Leu Gln Leu Gly His Gly Leu Lys Asp Phe Val His Lys Thr 50 55 60 Lys Gly Gln Ile Asn Asp Ile Phe Gln Lys Leu Asn Ile Phe Asp Gln 65 70 75 80 Ser Phe Tyr Asp Leu Ser Leu Gln Thr Ser Glu Ile Lys Glu Glu Glu 85 90 95 Lys Glu Leu Arg Arg Thr Thr Tyr Lys Leu Gln Val Lys Asn Glu Glu 100 105 110 Val Lys Asn Met Ser Leu Glu Leu Asn Ser Lys Leu Glu Ser Leu Leu 115 120 125 Page 4 ZLL-PCT0895_ST25 Glu Glu Lys Ile Leu Leu Gln Gln Lys Val Lys Tyr Leu Glu Glu Gln 130 135 140 Leu Thr Asn Leu Ile Gln Asn Gln Pro Glu Thr Pro Glu His Pro Glu 145 150 155 160 Val Thr Ser Leu Lys Thr Phe Val Glu Lys Gln Asp Asn Ser Ile Lys 165 170 175 Asp Leu Leu Gln Thr Val Glu Asp Gln Tyr Lys Gln Leu Asn Gln Gln 180 185 190 His Ser Gln Ile Lys Glu Ile Glu Asn Gln Leu Arg Arg Thr Ser Ile 195 200 205 Gln Glu Pro Thr Glu Ile Ser Leu Ser Ser Lys Pro Arg Ala Pro Arg 210 215 220 Thr Thr Pro Phe Leu Gln Leu Asn Glu Ile Arg Asn Val Lys His Asp 225 230 235 240 Gly Ile Pro Ala Glu Cys Thr Thr Ile Tyr Asn Arg Gly Glu His Thr 245 250 255 Ser Gly Met Tyr Ala Ile Arg Pro Ser Asn Ser Gln Val Phe His Val 260 265 270 Tyr Cys Asp Val Ile Ser Gly Ser Pro Trp Thr Leu Ile Gln His Arg 275 280 285 Ile Asp Gly Ser Gln Asn Phe Asn Glu Thr Trp Glu Asn Tyr Lys Tyr 290 295 300 Gly Phe Gly Arg Leu Asp Gly Glu Phe Trp Leu Gly Leu Glu Lys Ile 305 310 315 320 Tyr Ser Ile Val Lys Gln Ser Asn Tyr Val Leu Arg Ile Glu Leu Glu 325 330 335 Asp Trp Lys Asp Asn Lys His Tyr Ile Glu Tyr Ser Phe Tyr Leu Gly 340 345 350 Asn His Glu Thr Asn Tyr Thr Leu His Leu Val Ala Ile Thr Gly Asn 355 360 365 Val Pro Asn Ala Ile Pro Glu Asn Lys Asp Leu Val Phe Ser Thr Trp 370 375 380 Asp His Lys Ala Lys Gly His Phe Asn Cys Pro Glu Gly Tyr Ser Gly 385 390 395 400 Page 5 ZLL-PCT0895_ST25 Gly Trp Trp Trp His Asp Glu Cys Gly Glu Asn Asn Leu Asn Gly Lys 405 410 415 Tyr Asn Lys Pro Arg Ala Lys Ser Lys Pro Glu Arg Arg Arg Gly Leu 420 425 430 Ser Trp Lys Ser Gln Asn Gly Arg Leu Tyr Ser Ile Lys Ser Thr Lys 435 440 445 Met Leu Ile His Pro Thr Asp Ser Glu Ser Phe Glu 450 455 460 <210> 4 <211> 32 <212> PRT <213> universal T cell epitope <400> 4 Ile Leu Met Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Pro 1 5 10 15 Met Gly Leu Pro Gln Ser Ile Ala Leu Ser Ser Leu Met Val Ala Gln 20 25 30 <210> 5 <211> 79 <212> PRT <213> human ApoC-III fragment <400> 5 Ser Glu Ala Glu Asp Ala Ser Leu Leu Ser Phe Met Gln Gly Tyr Met 1 5 10 15 Lys His Ala Thr Lys Thr Ala Lys Asp Ala Leu Ser Ser Val Gln Glu 20 25 30 Ser Gln Val Ala Gln Gln Ala Arg Gly Trp Val Thr Asp Gly Phe Ser 35 40 45 Ser Leu Lys Asp Tyr Trp Ser Thr Val Lys Asp Lys Phe Ser Glu Phe 50 55 60 Trp Asp Leu Asp Pro Glu Val Arg Pro Thr Ser Ala Val Ala Ala 65 70 75 <210> 6 <211> 96 <212> PRT <213> human PCSK9 fragment <400> 6 Ala Gln Ser Ile Pro Trp Asn Leu Glu Arg Ile Thr Pro Pro Arg Tyr 1 5 10 15 Page 6 ZLL-PCT0895_ST25 Arg Ala Asp Glu Tyr Gln Pro Pro Asp Gly Gly Ser Leu Val Glu Val 20 25 30 Tyr Leu Leu Asp Thr Ser Ile Gln Ser Asp His Arg Glu Ile Glu Gly 35 40 45 Arg Val Met Val Thr Asp Phe Glu Asn Val Pro Glu Glu Asp Gly Thr 50 55 60 Arg Phe His Arg Gln Ala Ser Lys Cys Asp Ser His Gly Thr His Leu 65 70 75 80 Ala Gly Val Val Ser Gly Arg Asp Ala Gly Val Ala Lys Gly Ala Ser 85 90 95 <210> 7 <211> 154 <212> PRT <213> human ANGPTL3 fragment <400> 7 Ser Arg Ile Asp Gln Asp Asn Ser Ser Phe Asp Ser Leu Ser Pro Glu 1 5 10 15 Pro Lys Ser Arg Phe Ala Met Leu Asp Asp Val Lys Ile Leu Ala Asn 20 25 30 Gly Leu Leu Gln Leu Gly His Gly Leu Lys Asp Phe Val His Lys Thr 35 40 45 Lys Gly Gln Ile Asn Asp Ile Phe Gln Lys Leu Asn Ile Phe Asp Gln 50 55 60 Ser Phe Tyr Asp Leu Ser Leu Gln Thr Ser Glu Ile Lys Glu Glu Glu 65 70 75 80 Lys Glu Leu Arg Arg Thr Thr Tyr Lys Leu Gln Val Lys Asn Glu Glu 85 90 95 Val Lys Asn Met Ser Leu Glu Leu Asn Ser Lys Leu Glu Ser Leu Leu 100 105 110 Glu Glu Lys Ile Leu Leu Gln Gln Lys Val Lys Tyr Leu Glu Glu Gln 115 120 125 Leu Thr Asn Leu Ile Gln Asn Gln Pro Glu Thr Pro Glu His Pro Glu 130 135 140 Val Thr Ser Leu Lys Thr Phe Val Glu Lys 145 150 Page 7 ZLL-PCT0895_ST25 <210> 8 <211> 13 <212> PRT <213> pan HLA-DR binding epitope (PADRE) <400> 8 Ala Lys Phe Val Ala Ala Trp Thr Leu Lys Ala Ala Ala 1 5 10 <210> 9 <211> 391 <212> PRT <213> ApoC-III, PCSK9 and ANGPTL3 <400> 9 Ile Leu Met Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Pro 1 5 10 15 Met Gly Leu Pro Gln Ser Ile Ala Leu Ser Ser Leu Met Val Ala Gln 20 25 30 Arg Arg Ser Glu Ala Glu Asp Ala Ser Leu Leu Ser Phe Met Gln Gly 35 40 45 Tyr Met Lys His Ala Thr Lys Thr Ala Lys Asp Ala Leu Ser Ser Val 50 55 60 Gln Glu Ser Gln Val Ala Gln Gln Ala Arg Gly Trp Val Thr Asp Gly 65 70 75 80 Phe Ser Ser Leu Lys Asp Tyr Trp Ser Thr Val Lys Asp Lys Phe Ser 85 90 95 Glu Phe Trp Asp Leu Asp Pro Glu Val Arg Pro Thr Ser Ala Val Ala 100 105 110 Ala Gly Gly Gly Gly Ser Ala Gln Ser Ile Pro Trp Asn Leu Glu Arg 115 120 125 Ile Thr Pro Pro Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro Asp Gly 130 135 140 Gly Ser Leu Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Asp 145 150 155 160 His Arg Glu Ile Glu Gly Arg Val Met Val Thr Asp Phe Glu Asn Val 165 170 175 Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys Cys Asp 180 185 190 Ser His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly 195 200 205 Page 8 ZLL-PCT0895_ST25 Val Ala Lys Gly Ala Ser Gly Gly Gly Gly Ser Ser Arg Ile Asp Gln 210 215 220 Asp Asn Ser Ser Phe Asp Ser Leu Ser Pro Glu Pro Lys Ser Arg Phe 225 230 235 240 Ala Met Leu Asp Asp Val Lys Ile Leu Ala Asn Gly Leu Leu Gln Leu 245 250 255 Gly His Gly Leu Lys Asp Phe Val His Lys Thr Lys Gly Gln Ile Asn 260 265 270 Asp Ile Phe Gln Lys Leu Asn Ile Phe Asp Gln Ser Phe Tyr Asp Leu 275 280 285 Ser Leu Gln Thr Ser Glu Ile Lys Glu Glu Glu Lys Glu Leu Arg Arg 290 295 300 Thr Thr Tyr Lys Leu Gln Val Lys Asn Glu Glu Val Lys Asn Met Ser 305 310 315 320 Leu Glu Leu Asn Ser Lys Leu Glu Ser Leu Leu Glu Glu Lys Ile Leu 325 330 335 Leu Gln Gln Lys Val Lys Tyr Leu Glu Glu Gln Leu Thr Asn Leu Ile 340 345 350 Gln Asn Gln Pro Glu Thr Pro Glu His Pro Glu Val Thr Ser Leu Lys 355 360 365 Thr Phe Val Glu Lys Gly Gly Gly Gly Ser Ala Lys Phe Val Ala Ala 370 375 380 Trp Thr Leu Lys Ala Ala Ala 385 390 Page 9
Claims
We Claim:
1. A chimeric protein comprising polypeptides ApoC-III, PCSK-9 and ANGPTL3, wherein the ApoC-III, PCSK-9 and ANGPTL3 are coupled with each other via one or more suitable linker(s) as per Formula (I): Peptide A---L---Peptide B---L---Peptide C Formula (I) wherein, the Peptide A, Peptide B and Peptide C represents any of ApoC-III or PCSK-9 or ANGPTL3 polypeptide and wherein further each of Peptide A and Peptide C are linked to a suitable immunogenic carrier and wherein further Peptide A, Peptide B and Peptide C does not represent the same peptide and wherein L represents a suitable linker.
2. The chimeric protein as claimed in claim 1, wherein the immunogenic carrier is selected from the group consisting of diphtheria toxin (DT), keyhole limpet haemocyanin (KLH), CRM, preferably CRM197, a tetanus toxoid (TT), Pan HLA-DR binding epitope (PADRE), universal T cell epitope) Protein D or any other protein or peptide containing helper T-cell epitopes.
3. The chimeric protein as claimed in claim 1 wherein the linker L comprises group of peptides selected from glycine-glycine-glycine-glycine-serine (GGGGS) or 15 amino acid residue (GGGGS)3, lysine-arginine (KR), arginine-arginine (RR) or arginine-lysine-arginine (RKR).
4. The chimeric protein as claimed in claim 1 wherein chimeric protein is according to Formula (II): Universal T cell epitope---L1---ApoC-III---L2---PCSK-9---L2---ANGPTL3---L2--- PADRE Formula (II) wherein, ApoC-III represents Human Apolipoprotein C-III, PCSK-9 represents Human Proprotein convertase subtilisin / kexin type 9, ANGPTL3 represents Human Angiopoietin- like protein 3, PADRE represents Pan HLA-DR binding epitope (Universal active peptide that activates T cells) L1 represents Linker 1 having amino acid sequence selected from lysine-arginine (KR), arginine-arginine (RR) or arginine-lysine-arginine (RKR) and arginine- 42arginine (RR) and L2 represents Linker 2 which is one or more of the amino acids glycine and serine selected from (GGGXX) n and (XGGGS) n, wherein n is greater than or equal to 1 but less than 6, wherein XX represents any amino acid residue, preferably GGGGS.
5. The chimeric protein as claimed in claim 1, wherein the ApoC-III comprises amino acids sequence as set forth in SEQ ID No 1 or 5.
6. The chimeric protein as claimed in claim 1, wherein the ApoC-III comprises 2 to 10 amino acids, 10 to 25 amino acids, 25 to 60 amino acids, 60 to 84 amino acids, 16 to 99 amino acids or 84 to 99 amino acids of SEQ ID No 1 or 5.
7. The chimeric protein as claimed in claim 1, wherein the PCSK-9 comprises amino acids sequences as set forth in SEQ ID No 2 or 6.
8. The chimeric protein as claimed in claim 1, wherein the PCSK-9 comprises 2 to 10 amino acids, 10 to 25 amino acids, 25 to 60 amino acids, 60 to 85 amino acids, 85 to 100 amino acids, 100 to 200 amino acids, 150 to 250 amino acids, 200 to 350 amino acids, 300 to 400 amino acids or 400 to 650 amino acids of SEQ ID No 2 or 6.
9. The chimeric protein as claimed in claim 1, wherein the ANGPTL3 comprises amino acids sequence as set forth in SEQ ID No 3 or 7.
10. The chimeric protein as claimed in claim 1, wherein the ANGPTL3 comprises 2 to 10 amino acids, 10 to 25 amino acids, 25 to 60 amino acids, 60 to 85 amino acids, 85 to 100 amino acids, 15 to 165 amino acids or 100 to 180 amino acids of SEQ ID No 3 or 7.
11. The chimeric protein as claimed in claim 1, wherein the ApoC-III comprises any one of SEQ ID No: 1 or 5; the PCSK-9 comprises any one of SEQ ID No: 2 or 6; and the ANGPTL3 comprises any one of SEQ ID No: 3 or 7 or any modification such as insertion, deletion or substitution of atleast one amino acid from said sequences.
12. The chimeric protein as claimed in claim 1, comprising epitopes or mimotopes or fragments encompassing regions between amino acid numbers 16 to 99 of human ApoC-III (SEQ ID No: 5) and fragments encompassing regions between amino acids numbers 150 to 250 of human PCSK9 (SEQ ID No: 6) and fragments encompassing regions between amino acids numbers 15 to 165 of human ANGPTL3 (SEQ ID No: 7).
13. The chimeric protein as claimed in claim 1, wherein the chimeric protein comprising ApoC- III, PCSK9 and ANGPTL3 that are conjugated with suitable immunogenic carriers wherein 43ApoC-III, PCSK9 and ANGPTL3 having amino acid sequences as set forth in SEQ ID No: 5, SEQ ID No: 6 and SEQ ID No: 7 respectively.
14. The chimeric protein as claimed in claim 1, wherein the immunogenic carriers are universal T cell epitope having SEQ ID No: 4 and Pan HLA-DR binding epitope (PADRE) having SEQ ID No:
8.
15. The chimeric protein as claimed in claim 1, comprises amino acid sequence as set forth in SEQ ID No:
9.
16. A vector comprising gene encoding the chimeric protein as claimed in claim 1.
17. The chimeric protein as claimed in claim 1, wherein the chimeric protein is an immunogen.
18. The immunogenic composition, preferably vaccine comprising the chimeric protein as claimed in claim 1 and suitable excipients.
19. The immunogenic composition, preferably vaccine as claimed in claim 18, wherein the suitable excipients comprising an adjuvant selected from alum, alum in combination with MF-59, TLR3 agonist selected from Poly(I:C), TLR 4 agonist selected from Monophosphoryl Lipid A or GLA and like, TLR5 agonist selected from Flagellin, TLR7 agonist selected from Gardiquimod and Imiquimod, TLR7 / 8 agonist selected from R848, NOD2 agonist selected from N-glycolyl-MDP, CpG-containing nucleic acid, QS21, stable oil in water emulsions Sepivac SWE™ or any Alum and Oil in water combination or MPL, or stable water in oil emulsion or alum and water in oil combination or any combination thereof inducing both humoral and durable effector T-Cell responses, interleukins, beta-sitosterol and the like.
20. A protein comprising polypeptides wherein the polypeptide is selected from ApoC-III or PCSK-9 or ANGPTL3 or any combination thereof wherein each polypeptide is coupled with immunogenic carrier.
21. The protein as claimed in claim 20, wherein the immunogenic carrier is selected from the group consisting of diphtheria toxin (DT), keyhole limpet haemocyanin (KLH), CRM, preferably CRM197, tetanus toxoid (TT), Pan HLA-DR binding epitope (PADRE), universal T cell epitope, virus like particle (VLP) or any other protein or peptide containing helper T- cell epitopes.
22. The protein as claimed in claim 20, wherein ApoC-III comprises any amino acid sequences as claimed in claim 5 and claim 6. 4423. The protein as claimed in claim 20, wherein PCSK-9 comprises any amino acid sequences as claimed in claim 7 and claim 8.
24. The protein as claimed in claim 20, wherein ANGPTL3 comprises any amino acid sequences as claimed in claim 9 and claim 10.
25. The protein as claimed in claim 20, wherein the immunogenic carriers are universal T cell epitope having SEQ ID No: 4 and Pan HLA-DR binding epitope (PADRE) having SEQ ID No:
8.
26. The protein as claimed in claim 20, wherein the protein is an immunogen.
27. The immunogenic composition, preferably vaccine comprising the protein as claimed in claim 20 and suitable excipients as claimed in claim 19.
28. The immunogenic composition, preferably vaccine as claimed in any preceding claims used in the treatment of diseases mediating through ApoC-III and / or PCSK9 and / or ANGPTL3.
29. The immunogenic composition, preferably vaccine as claimed in any preceding claims used in the treatment of dyslipidemia and / or atherosclerosis and / or any cardiovascular disease.
30. The immunogenic composition, preferably vaccine as claimed in any preceding claims administered alone or co-administered with an additional dyslipidemia therapeutic agent or therapeutic agent that is used in the treatment of atherosclerosis.
31. The immunogenic composition, preferably vaccine as claimed in any preceding claims wherein the said vaccine is administered in a subject at dose between 10 µg and 1000 µg, preferably between 25 µg and 100 µg.
32. The protein or immunogenic composition, vaccine or vaccine combination selected from ApoC-III and / or PCSK9 and / or ANGPTL3 or any combination thereof, preferably vaccine as claimed in any preceding claims used in the treatment of diseases mediating through ApoC-III and / or PCSK9 and / or ANGPTL3.
33. The protein or immunogenic composition, vaccine or vaccine combination selected from ApoC-III and / or PCSK9 and / or ANGPTL3 or any combination thereof, preferably vaccine as administered alone or co-administered with an additional dyslipidemia therapeutic agent or therapeutic agent that is used in the treatment of dyslipidemia with other claimed in any preceding claims used in the treatment of dyslipidemia and / or atherosclerosis and / or any cardiovascular disease. 45
Citation Information
Patent Citations
Vaccine
US20040052809A1
Novel Scaffolded HIV-1 Vaccine Immunogens
US20190125890A1
PCSK9 vaccine and methods of using the same
WO2015123291A1
Immunogens, compositions, and methods for treating dyslipidemia
WO2017205454A1
Novel peptide based PCSK9 vaccine
WO2018189705A1
